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Summary 
Summary 
Ethiopia as one of the malaria endemic countries has adopted artemisinin-based combination 
therapy (ACT) in the form of Artemether-Lumefantrine (AL) as first-line treatment for 
uncomplicated falciparum malaria in 2004. The broad introduction of the drug was achieved in 
2006 including our study area Jimma, where we conducted a prospective open-label randomized 
trial by comparing AL to Quinine (Q) and Atovaquone-Proguanil (AP) to address the 
controversial reports concerning neuro-ototoxicity and resulting hearing loss due to artemisinin 
based treatments of uncomplicated falciparum malaria. In addition, the clinical and 
parasitological efficacy of the study drugs were evaluated and underlying molecular markers 
correlated with resistance were determined in the parasite isolates.  
Patients > 5 years of age and eligible for complete audio-vestibular evaluations with 
uncomplicated falciparum malaria were recruited from April to August 2006 in Jimma and the 
patients were randomized to receive either AL (n=30) or Q (n=35) or AP (n=32). Tolerability 
assessments and comprehensive audio-vestibular evaluations were also performed after 
chemotherapy on follow-up days 7, 28, and 90. Clinical assessments included otoscopy, Rinne 
and Weber tests, neurological examinations (Romberg, Unterberger’s stepping, gait, finger-to-
nose, nystagmus, Halmagyi test); neuro-otologic evaluation was performed by transitory evoked 
otoacoustic emissions (TEOAE), distortion product otoacoustic emissions (DPOAE), pure tone 
audiometry (PTA), and brainstem evoked response audiometry (BERA). 
On the other hand, genotyping of the isolates by molecular analysis of the surface antigens msp-1 
and msp-2 genes was performed to determine clonality and to distinguish between reinfection 
and recrudescence (resistance) if parasitaemia occurred after day 7. Molecular markers 
associated with drug resistance were determined by sequencing of pfserca and pfcytb genes; and 
by amplification and enzyme digestion (RFLP) of pfmdr1 and pfdhfr genes.  
Tolerability was good, no severe adverse effects were observed related to the drugs upon malaria 
treatment and as a result patient compliance was high. All malaria symptoms were resolved by 
day 7 except few patients with headache in all groups. As expected, a significant proportion of 
patients complained perceived hearing problem in the Q group, but not in the AL or AP group. 
Tinnitus was experienced with some patients in all groups from day 0 through 7, significantly  
IV 
Summary 
increasing in the Q group. There was significant reversible hearing loss elicited on day 7 among 
patients treated with Q but not treated with AL or AP as depicted by PTA and DPOAE. There 
was no evidence of drug-induced neurotoxic brainstem lesions from interpeak latencies analysis 
of BERA measurements in all treatment groups. No early treatment failure occurred in any drug 
group, but late treatment failures or recrudescences were observed ranging from day 24 to 70, in 
the Q group (n=4, 11.4%; on day 24, 28, 28, 40) and AP group (n=2, 6.3%; on day 28, 28). In the 
AL group, one possible recrudescence on day 70 (n=1, 3.3%) was detected. Rate of gametocyte 
clearance from the peripheral blood was very fast and efficient with AL compared to the other 
drugs.  
The investigation of the molecular markers showed a high proportion of pfmdr1 N86Y mutation 
(84.5%) in the parasite isolates of all treatment groups including among the four recrudescent 
isolates in the Q group. There was a high proportion of pfdhfr mutations or single nucleotide 
polymorphisms (SNPs) in codons N51I (98.8%), C59R (87.6%), and S108N (100.0%), the triple 
mutation occurred in 83.3% of the isolates. There were twelve SNPs detected in the pfserca gene 
of the AL treatment group, six new and six previously described mutations, but all the strains 
were treatment sensitive. There was no mutation in codon 268 of the pfcytb gene investigated for 
those recrudescent strains in the AP treatment group. 
In conclusion, there was no neuro-ototoxic effect of the AL in the auditory and vestibular 
system. No transient or irreversible hearing loss was detected in the study except among patients 
in the Q treatment group with transient cochlear hearing loss due to reversible outer hair cell 
impairment. Therefore, AL is effective, safe and tolerable for treatment of uncomplicated 
falciparum malaria. The high degree of mutations observed in the pfmdr1 and pfdhfr are 
reminiscent of the impact of previously used first-line antimalarials chloroquine and 
sulphadoxine-pyrimethamine in this area. Mutations in the artemisinin-related gene Pfserca were 
observed in an ACT-naive population and are considered to have spontaneously developed 
without resistance-conferring effects. However, they may serve as baseline information for 
further allelic selection that may happen due to long-term use of AL in the area.  
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Zusammenfassung 
Äthiopien gilt als in weiten Teilen als  Malaria-endemisches  Gebiet. 2004 wurde dort eine 
Artemisinin-basierte Kombinationstherapie (ACT) in Form von Artemether-Lumefantrin (AL)  
als Mittel der Wahl bei unkomplizierter Malaria tropica erklärt. Eine flächendeckende 
Einführung des Medikamentes wurde in unserem Studiengebiet der Region Jimma erst 2006 mit 
Beginn der Studie erreicht. Aufgrund kontroverser Berichte über Neurotoxizität und in Folge 
resultierendem Hörverlust unter ACTs bei Malaria tropica führten wir eine prospektive offene 
randomisierte drei-armige Studie mit AL, Chinin (Q) und Atovaquone-Proguanil (AP) durch. 
Zusätzlich wurden die klinische und parasitologische Effektivität der Studienmedikamente 
evaluiert und Resistenz-assoziierte molekulare Marker der Isolate bestimmt.  
Patienten mit unkomplizierter Malaria, die älter als fünf Jahre und geeignet für eine audio-
vestibuläre Untersuchung waren, wurden von April bis August 2006 in Jimma rekrutiert und für 
die Studienmedikamente randomisiert (AL: n=30, Q: n=35, AP: n=32). Verträglichkeit und 
umfangreiche audio-vestibuläre Untersuchungen wurden vor Therapie bei Aufnahme und 
während des Follow-up an den Tagen 7, 28 und 90 durchgeführt. Klinische Untersuchungen 
beinhalteten Otoskopie, Rinne und Weber Test sowie neurologische Tests (Romberg, 
Unterberger Tretversuch, DGI, Finger-Nase-Versuch, Nystagmus-Prüfung, Halmagyi Test); die 
neuro-otologische Beurteilung wurde mittels TEOAE, DPOAE, PTA and BERA durchgeführt.  
Zudem wurde eine Genotypisierung der Isolate mittels molekularer Analyse von 
Oberflächenantigenen msp-1 und msp-2 zur Bestimmung der Klonalität und zur Differenzierung 
in Neuinfektion und Rekrudeszenz (Resistenz) bei Parasitämie ab Tag 7 durchgeführt. 
Molekulare Marker, die mit Medikamentenresistenz assoziiert werden, wurden mittels 
Sequenzierung des pfserca und pfcytb Gens sowie durch Amplifikation und Enzymverdau der 
Gene pfmdr1 und pfdhfr bestimmt.  
Es zeigte sich eine gute Verträglichkeit der Medikamente, keine schweren Nebenwirkungen 
wurden beobachtet, daher war die Compliance der Patienten sehr hoch. Bis auf Kopfschmerzen 
in wenigen Fällen gaben die Patienten keine der vor Therapie bestehenden Symptome an Tag 7 
an. Wie erwartet gab ein signifikanter Anteil an Patienten in der Q Gruppe Hörprobleme an, 
jedoch nicht in den anderen beiden Armen. An Tinnitus litten einige Patienten in allen Gruppen  
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ein signifikanter reversibler Hörverlust mittels PTA und DPOAE gemessen im Vergleich zu den 
anderen beiden Gruppen. Medikamenten-induzierte pathologische vestibulare Befunde oder 
Hinweise auf Hirnstammläsionen in der BERA Latenzanalyse wurden in keiner der Gruppen 
gefunden. Frühe Therapieversager traten nicht auf, späte Therapieversager, so genannte 
Rekrudeszenzen, wurden ab Tag 24 bis Tag 70 beobachtet. In der Q Gruppe waren es 4 
Therapieversager (11,4%), in der AP Gruppe zwei (6,3%) und in der AL Gruppe kam es zu einer 
möglichen Rekrudeszenz an Tag 70 (n=1, 3,3%). Die Gametozyten wurden mit AL effizienter 
und wesentlich schneller aus dem peripheren Blut entfernt als mit den anderen Medikamenten.  
Bei der Untersuchung der molekularen Marker zeigte sich in 84,5% aller Isolate die Tyrosin-
Mutation am Codon 86 des pfmdr Gens, die vier rekrudeszenten Isolate in der Q Gruppe trugen 
ebenfalls die Mutation. Die Punktmutationen in den Codons N51I, C59R, und S108N des pfdhfr 
Gens konnten zu 98,8%, 87,6% bzw. 100,0% nachgewiesen werden, die Dreifach-Mutation trat 
bei 83,3% der Isolate auf. Im pfserca Gen der AL Gruppe wurden sechs neue und sechs kürzlich 
beschriebene Punktmutationen gefunden, diese fanden sich ausschließlich sensitiven Stämmen. 
Keine Mutation fand sich am Codon 268 des pfcytb Gens in den rekrudeszenten Stämmen des 
AP Therapiearmes. 
Zusammenfassend lässt sich sagen, dass keine neurotoxischen Wirkungen von AL auf das 
auditorische oder vestibuläre System festgestellt werden konnten. Bis auf den transienten 
cochleären Hörverlust unter Chinin durch den reversiblen Schaden an den äußeren Haarzellen 
kam es zu keinem transienten oder irreversiblen Hörschaden bei den Studienteilnehmern. AL hat 
sich als effektives, sicheres und gut verträgliches Medikament gegen die unkomplizierte Malaria 
tropica erwiesen.  
Der hohe Grad an beobachteten Mutationen im pfmdr und pfdhfr Gen läßt sich am ehesten  auf 
den noch kürzlich ausgedehnten Gebrauch von Chloroquin  und Sulfadoxin-Pyrimethamin in 
dieser Gegend zurückzuführen. Mutationen im pfserca Gen, das mit der Artemisinin-Wirkung in 
Zusammenhang gebracht wird, wurden in einer ACT-naiven Population beobachtet; es wird 
daher angenommen, dass sie sich spontan und wahrscheinlich ohne eine Resistenz-vermittelnde 
Wirkung entwickelt haben. Sie stellen jedoch eine wichtige Ausgangsposition zur weiteren 
Beobachtung der Selektion von Mutationen unter Medikamentendruck dar, wie er bei 
Langzeitgebrauch zu erwarten sein wird. 
VII 
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 Introduction 
 
1.  Life Cycle and Development of the Parasite 
Plasmodium falciparum is a eukaryotic protozoan parasite in the phylum Apicomplexa.  The 
parasite’s life cycle comprises several stages, which are morphologically, biochemically, and 
antigenically distinct developing in mosquito and human hosts (Fujioka and Aikawa, 1999). A 
schematic representation of this complex life cycle is shown in Fig. 1. 
 
Figure 1. The Life Cycle of Plasmodium falciparum (Florens et al., 2002)   
 
Infection of the human host starts when an infected female Anopheles mosquito takes a blood-
meal. This event is accompanied by the injection of the contents of the saliva with anticoagulant, 
containing usually less than 50 infectious sporozoites (Beier et al., 1991a, 1991b; Ponnudurai et 
al., 1991). The sporozoites are efficiently cleared within minutes from the blood-stream and 
reach the liver. Within the hepatocytes sporozoites become round or oval trophozoites and 
develop into schizonts followed by nuclear multiplication. In an average duration of 6.5 days, 
tens of thousands of infective merozoites are formed from the schizont and are released into the 
blood stream and start to invade erythrocytes. No hypnozoites occur in the case of Plasmodium  
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falciparum (Gratzer et al., 1993; Murphy et al., 1989). Then the merozoites adhere to 
erythrocytes surface, via their apical end, containing rhoptries and micronemes. These organelles 
then facilitate the entry of merozoites into erythrocytes cytoplasm. Inside the erythrocytes, 
merozoites being in parasitophorous vacuole membrane develop into ring-forms, trophozoites, 
and schizonts. When a schizont ruptures, 8 to 32 new merozoites from erythrocyte and cell 
debris and toxic by-products are released into the blood stream, which is the completion of the 
first erythrocytic schizogony cycle. This cycle continues to occur resulting the periodic 
paroxysmal symptoms such as fever (after each 48 h or less for P. falciparum) and chills as well 
as the sequestration of late trophozoites and schizonts in capillaries in almost all organs. After 
several erythrocytic cycle gametocytogenesis happens where a few percent of the merozoites 
develop into male and female gametocytes in a ratio of 1:4, respectively (Aikawa, 1988; Read et 
al., 1992; Ward et al., 1993). They are the sex-cells which can only develop further if they are 
taken up by a feeding Anopheles mosquito. 
 
Once gametocytes are taken into the mosquito midgut the change in temperature, pH and carbon 
dioxide concentration, together with the presence of a mosquito exflaggelation factor (MEF) 
(Nijhout et al., 1979), possibly xanthurenic acid (Garcia et al., 1998) triggers them within 
minutes to escape from the erythrocyte and differentiate into gametes (Carter et al., 1988). A 
female gametocyte develops into one macrogamete; a male gametocyte develops into 8 
exflaggelating microgametes consisting of nucleus associated with a flagellum. The motile 
microgamete attaches to the female gamete with which they fuse to form a zygote. Fertilization 
and zygote formation occurs within 10-30 minutes after ingestion of a blood meal by mosquito 
(Carter et al., 1988). The zygote differentiates into a motile ookinete over the next few hours. 
After the ookinete has crossed the insect midgut membrane by the help of enzymes, like 
chitinase, it changes into oocyst in the haemocoel and undergoes multiplication. As a result 
thousands of sporozoites are formed and migrate to the mosquitoes salivary glands. Then the 
mosquito will be ready to transmit the sporozoites to human (Shahabuddin et al., 1994; 
Dinglasan et al., 2007).  
  
2.  Aetiology and Pathogenesis of Malaria    
Infection by malaria parasites may lead to a variety of clinical syndromes, depending on a 
combination of different elements including the virulence of the parasite isolate and a variety of  
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host related factors such as host’s immunity or genetic make-up. All types of malaria initially 
manifest with common mild or uncomplicated symptoms such as fever, chills, malaise, 
headache, arthralgia, abdominal pain, nausea, vomiting, anorexia, diarrhea or mild anemia and in 
some patients disease may progress into severe malaria and fatality. Severe malaria and death are 
more often seen in cases of P. falciparum infection. The early paroxysmal manifestations are 
related to completion of erythrocytic schizogony and release of merozoites along with waste 
substances. The involvement of red cells makes malaria a potentially multisystem disease, as 
every organ of the body is reached by the blood (Omer et al., 2003; Greenwood et al., 2008).  
Pathogenesis is a multifactor event from both host and parasite. The waste substances released 
into the blood, such as red cell membrane products, hemozoin pigment, plasmodial DNA and 
other toxic factors such as glycosylphosphatidylinositol (GPI), activate macrophages and 
endothelial cells to secrete cytokines and inflammatory mediators. Tumor necrosis factor, 
interferon-γ, interleukin-1, interleukin-6, interleukin-8, macrophage colony-stimulating factor, 
lymphotoxin, superoxide and nitric oxide (NO) are responsible for systemic manifestations of 
malaria such as aneamia, thrombocytopenia, immunosuppression, coagulopathy, and central 
nervous system involvement among the others   (Mackintosh et al., 2004; Clark et al., 2006; 
Parroche et al., 2007; Schumann, 2007; Chakravorty et al., 2008). Hemozoin has also been 
linked to the induction of apoptosis in developing erythroid cells in the bone marrow, thereby 
causing anemia (Awandare et al., 2007; Lamikanra et al., 2009).  
The pathogenesis of severe malaria involves a series of interactions such as rosetting, 
cytoadherence, and sequestration of infected erythrocytes in the vital organs ultimately blocking 
blood flow, local oxygen supply, mitochondrial ATP synthesis, and stimulating cytokine 
production resulting in various organ dysfunctions (Ho and White, 1999; Clark et al., 2006; van 
der Heyde et al., 2006; Maier et al., 2008). In addition erythrocytes membrane rigidity; 
endothelial activation, dysfunction and injury; and altered thrombostasis have been found to be 
involved in the development of severe malaria (Cooke et al., 2004; Chakravorty et al., 2008; 
Park et al., 2008). 
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2.1. Uncomplicated Falciparum Malaria  
Uncomplicated falciparum malaria is defined as symptomatic malaria without signs of severity 
or complications or evidence (clinical or laboratory) of vital organ dysfunction. The signs and 
symptoms of uncomplicated falciparum malaria are nonspecific. Uncomplicated malaria is the 
mild form of the disease which presents as a febrile illness with headache, tiredness (fatigue), 
muscle and joint aches, abdominal pains, rigors (severe shivering), perspiration, nausea, anorexia 
and vomiting. Parasitaemia for uncomplicated falciparum malaria is defined as 1000 to 100,000 
asexual parasite/µl of blood for low to moderate transmission areas and 2000 to 200,000 asexual 
parasites/µl of blood for high transmission areas (WHO, 2003; WHO, 2006; WHO, 2010).  
 
2.2. Severe Falciparum Malaria 
Severe malaria usually manifests with one or more of the following clinical or laboratory 
features: coma (cerebral malaria), prostration, impaired consciousness, multiple convulsions, 
metabolic acidosis, severe anaemia, hypoglycaemia, acute renal failure, acute pulmonary 
oedema, abdominal bleeding, respiratory distress (acidotic breathing), circulatory collapse, 
jaundice, haemoglobinuria, hyperlactataemia, hyperparasitaemia.  By this stage of the disease, 
the case fatality in people receiving treatment is typically 10–20%. However, if left untreated, 
severe malaria is fatal in the majority of cases (Chen et al., 2000; Miller et al., 2002; Mackintosh 
et al., 2004; WHO, 2006; WHO, 2010 ).   
 
3.  Overview of Molecular Biology  
Plasmodium falciparum belongs to the subgenus Laverania along with Plasmodium reichenowi, 
a chimpanzee malaria parasite, and both are closely related based on phylogenetic studies of 
small subunit ribosomal RNA (ssrRNA) and Cytochrome b gene sequences.  Whereas the other 
four malaria parasites that infect human, P. vivax, P. ovale, P. malariae and the monkey parasite 
P. knowlesi belong to the subgenus Plasmodium and they are not closely related to P. falciparum 
(Qari et al., 1996; Perkins et al., 2002; Tanabe et al., 2004).  
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The nuclear genome of Plasmodium falciparum is comprised of 14 chromosomes, ranging in size 
from approximately 0.643 to 3.29 Mb, and total size is 22.8 Mb. The genome encodes about 
5,300 genes. It is the most (A + T)-rich genome sequenced to date comprising 80.6% (Gardner et 
al., 2002). The P. falciparum analogous chromosomes differ considerably in size between 
isolates; one of the modes of generating chromosomal polymorphism is deletion/duplication 
(Corcoran et al., 1986). Genes that are involved in antigenic variation are concentrated in the 
subtelomeric regions of the chromosomes. This can be attributed to the feature of subtelomere 
regions to recombine more readily than other parts of the genome, thus generating variation in 
gene products that play role in avoidance of host immune response and resistance to 
chemotherapy (Scherf et al., 2001). Apart from the nuclear genome, there are the plastid 
(apicoplast) DNA (plDNA) genome and the mitochondrion DNA (mtDNA) genome. These also 
encode factors for vital cellular activities which may serve as target for chemotherapy (Preiser et 
al., 1995, 1996; Wilson et al., 1996).    
 
Completion of the entire life cycle offers many opportunities for genetic recombination and 
mutation events during numerous rounds of DNA replication. Genetic recombination can 
generate novel beneficial alleles, or combinations of alleles to the parasite, that can spread 
through the population driven by positive selection. Recombination rate is also influenced by 
intensity of transmission by mosquitoes, diversity of local parasite populations, and 
chromosomal locations of specific DNA sequences (Jiang et al., 2011). A study by Walliker et 
al. (1987) showed that mixture of cloned P. falciparum parasites differing in enzymes, drug 
sensitivity, antigens and chromosome patterns being transmitted into mosquitoes have resulted 
extensive rearrangements in their genomes after cross fertilization. Then it was extrapolated that 
a mosquito infection by mixtures of genetically distinct parasites from patient would provide the 
mechanisms for generating novel genotypes. These differing genotypes or clones of Plasmodium 
falciparum can be determined using regions of highly polymorphic genes coding for surface 
proteins; merozoite surface proteins 1 and 2 (MSP-1 and MSP-2), and glutamate-rich protein 
(GLURP) as markers with PCR-based methods. They are particularly important tools in 
distinguishing recrudescence from reinfection of the parasite (Färnert et al., 2001).  
 
 
5 
 
Introduction 
4.  Epidemiology 
In spite of enhanced control efforts, malaria continues to be a major public health problem in 108 
countries mostly in Africa and Southeast Asia and Plasmodium falciparum is endemic in most of 
the countries. WHO estimates that in 2009, a reported 225 million cases of malaria occurred 
worldwide and 78% of these in Africa followed by 15% in Southeast Asia. About 781,000 fatal 
cases were registered, 91% in Africa. 85% of the global death toll comprises children under 5 
years of age. Almost all deaths are caused by P. falciparum (World Malaria Report, 2010).  
 
Malaria in Ethiopia is caused by four human malaria species: P. falciparum, P. vivax, P. ovale 
and P. malariae. The prevalence of P. falciparum and P. vivax malaria in Ethiopia takes a 
significant share of about 60% and 40 %, respectively. P. malariae is found sporadically in some 
areas and P. ovale is reported rarely (Adhanom et al., 2006). The most deadly malaria is caused 
by P. falciparum, but two or more species can overlap in the same area and in a person at the 
same time (WHO, 2002). Malaria transmission in Ethiopia depends substantially on Anopheles 
arabiensis Patton (principal malaria vector in the country), a member of the Anopheles gambiae 
Giles complex, in the intermediate highlands of Ethiopia. Anopheles funestus Giles is the second 
most important malaria vector. Anopheles nili Theobald is an important local malaria vector in 
the low land region of south-west Ethiopia (Woyessa et al., 2002; Federal Ministry of Health 
Ethiopia, 2007). 
   
Malaria is a leading public health problem in Ethiopia where an estimated 75% of the total area 
of the country with altitudes below 2000m and about 50 million people (65-68% of the 
population) live in areas at risk of malaria and the problem is compounded by increasing 
frequency and magnitude of unstable malaria epidemics (WHO, 2002; Deressa et al., 2006; 
Federal Ministry of Health Ethiopia, 2008). In general malaria in the country is associated with 
altitude, rainfall, humidity and population movement, where the peak of malaria incidence 
follows the main rainfall season (July - September) each year. However, many areas in the south 
and west of the country have a rainfall season beginning earlier in April and May or have no 
clearly defined rainfall season. Depending on these rainfall patterns, transmission tends to be 
highly heterogeneous within each year as well as between years. Localized malaria epidemics 
occur almost every year somewhere in the country with occasional massive outbreaks affecting  
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most of the country at regular intervals of 5-8 years period (Kiszewski and Teklehaimanot, 2004; 
Negash et al., 2005, Jima et al., 2010). Also frequent malaria epidemics have been observed in 
highland areas of Ethiopia previously not known to allow transmission (Woyessa et al., 2004). In 
Jimma region, malaria transmission is seasonal with peaks from April to June and from 
September to December during and after the rainy seasons (Gürkov et al., 2008).  
 
 In this country, endemicity of malaria was reported for the first time by scientists from Britain 
and Italy starting from the mid 1930`s. Since then, many malaria epidemics were recorded in the 
country. For example, in 1958, an estimated 3.5 million people became infected of which about 
150,000 died (Fontaine et al., 1961). The disease is among the most important public health 
problems surpassing other communicable diseases such as infections with helminthes, protozoa, 
bacteria, and HIV (Federal Ministry of Health Ethiopia, 2005). For example, by 2002/2003 alone 
malaria was reported as the first cause of morbidity and mortality, accounting for 16% outpatient 
visits, 20% hospital admissions and 27% inpatient deaths. The year 2003 was also a time of 
large-scale malaria epidemics for the country from April to December resulting in 20 million 
clinical and confirmed cases and 3000 deaths, affecting 3368 localities in 211 districts (World 
Malaria Report, 2005). Again in 2007/2008, malaria was the first cause of morbidity and 
mortality in the country, accounting for 12% of out-patient visits and 9.9% of admissions 
(Federal Ministry of Health Ethiopia, 2008). Despite the current efforts to control malaria in 
Ethiopia, the situation has not improved, mainly due to the increasing problems of vector 
resistance to insecticides, low coverage of malaria preventive services, poor access to health 
care, rudimentary health service infrastructure, large population movements, limited financial 
and human resources, and unstable nature of malaria transmission resulting large-scale epidemics 
(World Malaria Report, 2005; Nigatu et al., 2009). 
 
5.  Antimalarial Treatment and Resistance 
There are different classes of antimalarial drugs with different biological activities, which are 
being in use or had been used for malaria treatment: (1) 4-Aminoquinolines- (Chloroquine, 
Amodiaquine, Piperaquine) with blood schizonticide activity (2) Arylaminoalcohols- (Quinine, 
Quinidine, Mefloquine, Halofantrine, Lumefantrine) with blood schizonticide activity (3) 
Sulfonamides and Sulfones- (Sulfadoxine, Sulfalene, Dapsone) with blood schizonticide and  
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tissue schizonticide activity (4) Biguanides- (Proguanil, Chlorproguanil) with blood 
schizonticide and tissue schizonticide activity  (5) Diaminopyrimidine- (Pyrimethamine) with 
blood schizonticide and tissue schizonticide activity (6) 8-Aminoquinoline- (Primaquine, 
Etaquine) with very mild blood schizonticide, tissue schizonticide, and gametocytocide activity   
(7) Sesquiterpene Lactones – (Artemisinin, Arteether, Artemether, Artesunate, 
Dihydroartemisinin) with blood schizonticide and gametocytocide activity (8) Naphthoquinone- 
(Atovaquone) with blood schizonticide and tissue schizonticide activity (9) Antibiotics- 
(Azithromycin, Clindamycin, Doxycycline, Tetracycline) with blood schizonticide and mild 
tissue schizonticide activity. Despite considerable efforts during the last century to eradicate or 
control falciparum malaria with chemotherapy being one of the armors, it remains to be the most 
prevalent and devastating parasitic disease in endemic countries. Emergence of drug resistance 
has been one of the important factors in hampering the control efforts. This was particularly 
evident during the Global Malaria Eradication Campaign launched by World Health 
Organization (WHO) in 1955 that extensive use of antimalarial drugs led to the selection of 
resistant parasites. The first reports confirming P. falciparum resistance to chloroquine came few 
years after introduction of the campaign (D'Alessandro and Buttiëns, 2001).  
 
Antimalarial drug resistance is due to reduced susceptibility of the parasite. It is the ability of a 
parasite strain to survive and/or multiply despite the administration and absorption of a medicine 
given in doses equal to/or higher than the usual recommended dosage provided that the drug gets 
access to the parasite (WHO, 2006). Drug resistance mechanisms that confer reduced 
susceptibility of the parasite can be due to mutations or changes in (duplications of) the copy 
number of genes encoding or relating to the drug targets in the parasite or influx/efflux pumps 
that affect intraparasitic concentrations of the drug. A single genetic event may be all that is 
required, or multiple unlinked events may be necessary for the resistance. A parasite strain can 
be resistant to two or more antimalarial drugs of different chemical classes and mode of actions a 
situation called multidrug resistance. Resistance to one drug may be selected by the parasite for 
another drug in which the mechanism of resistance is similar, a phenomenon known as cross-
resistance (White, 2004). P. falciparum resistance to antimalarial drugs can be manifested as 
early treatment failure (ETF) or late treatment failure (LTF) in patients. ETF means the 
persistence of clinical symptoms and parasitaemia until day 3 after initiation of chemotherapy  
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with parasite count > 25% of the day 0 count. In case of LTF, there will be recrudescence with 
identical clone after being cleared initially following chemotherapy on day 7 or any day after, 
depending on the type of antimalarial drug. For drugs such as amodiaquine, chloroquine, 
sulphadoxine-pyrimethamine, and atovaquone-proguanil late treatment failure is expected up to 
28 days, for mefloquine up to 63 days, and for artemether-lumefantrine up to 42 days as either 
clinical symptomatic or parasitological asymptomatic treatment failure (WHO, 2003).              
Resistance to antimalarial drugs has been documented in all classes of antimalarials, including 
the artemisinin derivatives, and it is a major threat to malaria control. Widespread and 
indiscriminate use of antimalarials exerts a strong selective pressure on falciparum malaria 
parasites to develop high levels of resistance. This has been observed with chloroquine and 
sulphadoxine-pyrimethamine having widespread and high level of resistances which made them 
being ruled out from their service against P. falciparum (World Malaria Report, 2009; WHO 
2010). Chloroquine resistance in P. falciparum may be multigenic and is initially conferred by 
mutations in a gene encoding a chloroquine resistance transporter (Pfcrt) and suggested to be 
augmented by mutations in a second transporter P-glycoprotein homologue-1(Pgh-1) encoded in 
multidrug resistance gene (Pfmdr1)  (Plowe, 2003). Resistance to quinine, lumefantrine, 
mefloquine and other structurally related Arylaminoalcohols in P. falciparum was associated 
with duplications of copy number of Pfmdr1 gene and in some cases its mutation (Cowman et 
al., 1994; Price et al., 1999; Sidhu et al., 2005). Resistance to the sulfonamides and sulfones, 
results from point mutations in the gene Pfdhps, which encodes the target enzyme 
dihydropteroate synthase (Alifrangis et al., 2003.). Resistance to atovaquone was associated with 
point mutations in the parasite’s gene Pfcytb, coding for cytochrome b, it is usually used in a 
fixed combination with proguanil. Resistance to pyrimethamine and proguanil’s metabolite 
cycloguanil is conferred by point mutations in the pfdhfr gene of the parasite that encodes the 
target dihydrofolate reductase enzyme (Srivastava and Vaidya, 1999; Alifrangis et al., 2003). The 
target for artemisinin drugs has been shown to be PfATPase6 enzyme (Eckstein-Ludwig et al., 
2003), hence some mutations in this gene were suggested to confer resistance in Plasmodium 
falciparum in vitro and in vivo (Jambou et al., 2005; Jung et al., 2005; Uhlemann et al., 2005 ).   
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5.1. Atovaquone -Proguanil Treatment 
Atovaquone-Proguanil is used for treatment and prophylaxis of falciparum malaria 
(Looareesuwan et al., 1999a, Overbosch et al., 2001). These partners target different metabolic 
features of the parasite. Atovaquone acts by inhibiting the mitochondrial electron transport and 
collapsing membrane potential and exerts its effect by binding to the parasite’s Cytochrome bc1 
complex, but proguanil also augments the atovaquone’s activity on the mitochondrial membrane. 
Proguanil in its active metabolite form cycloguanil acts by inhibiting the parasite’s enzyme 
dihydrofolate reductase (DHFR) (Srivastava and Vaidya, 1999). Clinical studies show close to 
100% efficacy rate for the combination therapy (Mulenga et al., 1999; Looareesuwan et al., 
1999b; Bustos et al., 1999). However, there are few reports of treatment failures among 
travellers and resistance mechanisms are attributable to mutations in the cytochrome b gene, 
Pfcytb (Codon: Tyr268Asn, Tyr268Ser or Tyr268Cys) and DHFR gene, Pfdhfr (Codons: A16V, 
N51I, C59R, S108N, S108T, I164L) of the parasite against atovaquone and proguanil, 
respectively (Reeder et al., 1997; Fivelman et al., 2002; Färnert et al., 2003; Schwartz et al., 
2003; Wichmann et al., 2004). Atovaquone-Proguanil is safe and well tolerated as evidenced 
from controlled trials either with placebo or other drugs (Nakato et al., 2007). 
 
5.2. Quinine Treatment  
Quinine is a cinchona alkaloid, Arylaminoalcohol drug with potent activity against asexual forms 
of all human malaria species, but not hypnozoite of P. vivax and P. ovale. It is also used for the 
treatment of sever falciparum malaria. Its potential mechanism of action seems to be the 
inhibition of heme polymerization in the parasite resulting in toxicity and death of the 
plasmodium, similar to other quinoline antimalarials (Slater and Cerami, 1992; Foley and Tilley, 
1998). Even though it is not completely elucidated, its action is linked to Pfmdr1- a multidrug 
resistance gene that encodes the parasite’s P-glycoprotein homologue-1 (Pgh-1). The Pgh-1 is 
localized in the digestive vacuole membrane of the parasite that may involve in the influx and 
efflux of drugs (Reed et al., 2000; Rohrbach et al., 2006). Quinine resistance is associated to 
Pfmdr1, either by increasing copy number of the gene or its polymorphism such as in 86N codon 
(Price et al., 2004; Sidhu et al., 2005; Sidhu et al., 2006). There are reports of falciparum malaria  
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quinine resistance mainly from Southeast Asia where it has been used extensively (Verdrager 
1986; Bunnag and Harinasuta, 1987; Giboda and Denis, 1988; Karbwang et al., 1994) and also 
in Africa (Jelinek et al., 1995).   Cinchonism is caused by quinine, which is a complex of 
symptoms such as tinnitus, reversible hearing loss, vertigo, blurred vision, headache, dysphoria, 
nausea, and diarrhea at therapeutic concentration of the drug for acute malaria (Bateman and 
Dyson, 1986; Roch et al., 1990; Newton and White, 1999).       
  
5.3. Artemisinin-Based Combination Therapy (ACT) Treatment 
Artemisinin is obtained from leaves of the herb qinghao or sweet wormwood (Artemisia annua). 
Artemisinin is structurally a sesquiterpen lactone with an endoperoxide bridge. The half-life of 
artemisinin and its derivatives lasts only for few hours; two to three hours, but can rapidly kill 
almost all asexual stages of Plasmodium falciparum and have effect on early stage gametocytes. 
The artemisinin derivatives, dihydroartemisinin (DHA), artesunate, artemether, and arteether can 
be used for treatment of malaria in artemisinin combination therapies with longer half-life 
partner drugs. The WHO currently recommends the following combination therapies, 
artemether/lumefantrine, artesunate/amodiaquine, artesunate/mefloqiune, artesunate/sulfadoxine-
pyrimethamine and dihydroartemisinin/piperaquine for the treatment of uncomplicated 
falciparum malaria in all areas where malaria is endemic. The ACTs are the most potent and 
rapidly acting of all antimalarials essentially in response to the global threat of multidrug 
resistant falciparum malaria (Haynes, 2006; WHO, 2010).  
     
         Artemisinin           Artemether               Artesunate                              Dihydroartemisinin                                                                 
Figure 2: Artemisinin and Its Derivatives  
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Artemether/lumefantrine (AL), a fixed dose in a 1:6 ratio (20mg/120mg) approved as Coartem®, 
now comprises nearly 75% of the 100 million or so ACT treatments used each year.  The six-
dose AL regimen based on number of tablets per dose according to pre-defined body weight 
bands (5–14 kg: 1 tablet; 15–24 kg: 2 tablets; 25–34 kg: 3 tablets; and > 34 kg: 4 tablets, given 
twice a day for 3 days) is currently the approved treatment regimen for acute, uncomplicated P. 
falciparum malaria. It is used for adults and paediatric patients with a body weight ≥5 kg, 
irrespective of the immune status of the patients to P. falciparum and of the local multidrug 
resistance situation, in the majority of endemic countries in Africa, Asia, Europe and Latin 
America where the drug is registered. Until the year 2009, 77 of 81 P. falciparum endemic 
countries including more than 40 sub-Saharan Africa countries had introduced ACT in their 
national drug policy, as first-line treatment for uncomplicated falciparum malaria (Cousin et al, 
2008; Makanga and Krudsood, 2009; World Malaria Report, 2009). Ethiopia adopted 
artemether/lumefantrine (AL) as first-line treatment for the treatment of uncomplicated 
falciparum malaria in 2004 by replacing sulfadoxine-pyrimethamine, which had a mean 
treatment failure rate 35.9% (range 21.7 – 53.4%) (Federal Ministry of Health Ethiopia, 2004).       
 
5.3.1. Mechanism of Action 
Artemisinin and its derivatives contain a stable endoperoxide
 
bridge, which is suggested to be 
cleaved by intraparasitic
 
heme. The cleaved endoperoxide becomes a carbon-centered free
 
radical 
which then functions as an alkylating agent, reacting
 
with parasite proteins 
(Kamchonwongpaisan and Meshnick, 2006). There have been different assertions about the 
artemisinins’ mechanism of action against Plasmodium falciparum, such as interference with 
parasite transport proteins, disruption of parasite mitochondrial electron transport, and 
modulation of host immune function (Golenser et al., 2006). Either inhibition of heme 
polymerization or heme dependent activation inside the parasite was also proposed as 
mechanism of action of artemisinin resulting in parasite toxicity and death (Pandey et al., 1999; 
Meshnick, 2002). Although a number of potential targets have been proposed and investigated, 
Eckstein-Ludwig et al. (2003) have shown with more concrete evidence that artemisinins act by 
selectively inhibiting PfATPase6, which is the parasite’s SERCA-type Ca
2+
-ATPase and was 
presumed to be the main target. Whereas the partner drugs along with artemisinins are 
structurally unrelated and possess different mechanisms of action with longer half-life (Cui and 
Su, 2009).  
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The Plasmodium falciparum sarco/ endoplasmic reticulum Ca
2+
-ATPase6 (PfSERCA) is the 
molecule responsible for refilling of calcium ion into the endoplasmic reticulum (ER) stores, 
which is critically important for cellular homeostasis and calcium signaling functions. P. 
falciparum has a single copy of SERCA sequence in the genome. PfSERCA protein is 
evolutionarily well conserved and composed of three cytoplasmic domains (A, actuator; N, 
nucleotide binding; P, phosphorylation), ten transmembrane (M1-M10) helices constituting the 
transmembrane gate and small lumenal loops. In the activated SERCA molecule A, N, and P 
domains together participate in regulating calcium binding and release into the ER lumen 
(Dahlström et al., 2008; Jambou et al., 2010).  
 
5.3.2. Efficacy and Resistance with ACT  
The rationale behind ACT is to improve treatment efficacy and to delay emergence of resistance 
to the potent artemisinin drugs which are the main constituents (WHO 2006). Even though 
significant clinical drug resistance to artemisinins was not reported at the time when our study 
was planned and conducted, there had been concern of in vitro drug resistance of field isolates 
from French Guiana and Northern Brazil (Jambou et al., 2005) and later high in vivo tolerance 
with evidence of delayed parasite clearance in Cambodia and Thailand to artemisinin derivative 
combination therapy was observed (Rogers et al., 2009). There have been also reports of in vivo  
resistance in Africa and Western Cambodia after a seven-day artemisinin monotherapy (Menard 
et al., 2005; Dondorp et al., 2009). Though the mechanisms of resistance have not been 
unequivocally described, mutations in the PfSERCA gene are correlated with decreased 
sensitivity or resistance to artemisinins. In light of this idea, it has been shown that an artificially 
produced single amino acid mutation L263E in the PfSERCA gene resulted in reduced inhibition 
of the Ca
2+
ATPase by artemisinin in vitro (Jung et al., 2005; Uhlemann et al., 2005). 
Furthermore from field isolate parasites in French Guiana a S769N single nucleotide 
polymorphism (SNP) in PfSERCA was associated with a significant rise of IC50 for artemether, 
which is a rise in the concentration of the drug that is required to kill half of the parasites 
(Jambou et al., 2005). A combination of two additional SNPs, E431K and A623E, was identified  
 
 
 
13 
Introduction 
in one clinical isolate from Senegal, which also demonstrated considerable increase in the IC50 to 
artemether (Jambou et al., 2005). Nevertheless, this has not been always the case because from 
subsequent studies in Africa only one S769N mutation was found in a parasite that has been fully 
sensitive to dihydroartemisinin in vitro (Cojean et al., 2006).   
 
More recently, polymorphisms in PfSERCA have been described in 100 P. falciparum isolates 
collected between 2002 and 2006 from South America, Asia and Africa. Full length coding 
sequence was determined for 56 isolates and partial gene sequence (positions 87 – 2862) was 
obtained for the rest of the isolates. Overall, 29 codons carried one or more type of mutations 
(SNPs). A total of 32 distinct SNPs or mutations were observed, of which 19 were non-
synonymous and 13 synonymous, resulting in an average of one SNP/115bp. A total of 19 
mutations had not been described previously. Some of the SNPs have been shown to be 
associated with increased IC50 of either artemether or artesunate (Jambou et al., 2010). Therefore 
from these underlying studies the variations or polymorphisms in PfSERCA (PfATPase6) may 
constitute a starting ground for artemisinins induced selection of resistant isolates with 
possibility of rise and spread of resistance to artemisinin drugs. Newly emerging polymorphisms 
or SNPs in the PfSERCA gene might be accountable for resistance to artemisinin derivative 
drugs. 
 
In addition to the artemisinin derivatives, the partner drugs in the ACT are shown to contribute to 
efficacy or resistance, for example mefloquine and lumefantrine. This was explained being 
attributable to Pfmdr1, a gene encoding the parasite’s transporter protein. There is evidence from 
studies in Cambodia and Thailand that increased copy numbers of Pfmdr1 was associated to 
mefloquine resistance after in vivo Artesunate + Mefloquine combination treatment failure; this 
was at the same time shown by higher in vitro mefloquine IC50 among the resistant isolates. On 
the other hand decreased copy numbers of Pfmdr1 enhances susceptibility of the parasite to 
mefloquine and lumefantrine (Price et al., 2004; Sidhu et al., 2006; Rogers et al., 2009). Other 
field studies have also shown selection of Pfmdr1 86N codon from recurrent infections after 
treatment with AL, which suggests that the codon could be a potential marker of lumefantrine 
tolerance/resistance in vivo (Sisowath et al., 2005; Sisowath et al., 2007).    
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5.3.3. Safety/ Tolerability/ Toxicity of ACT 
Artemisinin derivatives the main constituents in the ACT antimalarial treatments are considered 
to be effective and safe/tolerable. However from studies in animal models (mouse, rat, dog, and 
monkey), they are depicted to cause neurotoxicity targeting mainly the auditory and vestibular 
pathways. In an experimental study dogs and rats were treated with arteether and artemether at 
different doses via intramuscular route, the animals with higher dose (20mg/kg/day and above) 
exhibited ataxia, gait disturbance, loss of brainstem and eye reflexes, loss of pain response and 
spinal reflexes with histological evidences of neural degeneration and necrosis in brainstem, 
pons, medulla and spinal cord (Brewer et al., 1994).  Similar neurotoxic effects were observed in 
mice with constant administration of oral dihydroartemisinin suspended in water at doses higher 
than 200mg/kg/day for 28 days (Nontprasert et al., 2002). In another study, monkeys treated with 
high dose of arteether (24mg/kg/day) for 14 days but not 7 days demonstrated neuropathologic 
findings in brain section as injury to brainstem nuclei, reticular formation, vestibular system, and 
the auditory system (Petras et al., 1997). This phenomenon of toxicity was further shown by in 
vitro tests on cultured brainstem neuronal cells from rat and the cells sustained cytotoxicity and 
degeneration after treatment with artemisinin (Schmuck et al., 2002). 
 
Some case reports and clinical studies carried out in human subjects had conflicting reports 
whether artemisinin derivatives induce similar toxicity in the treatment of uncomplicated 
falciparum malaria patients with oral administration. 1,552 uncomplicated falciparum malaria 
patients, recruited from 2002 to 2004, were treated with a three day dose Artesunate + 
Sulphadoxine-Pyrimethamine and followed up on day 7 and 14, some of them complained of 
symptoms as vomiting 55(3.3%), nausea 47(3.0%), headache 39(2.5%), abdominal pain 
27(1.7%), dizziness or ataxia 27(1.7%), fever 16(1.0%), malaise 14(0.9%), and other symptoms 
10(0.6%). No neurological complications were reported except the dizziness and ataxia (Cairo et 
al., 2008). In an individual case of uncomplicated falciparum malaria, ataxia and slurred speech 
was reported after treatment with oral artesunate for 5 days (Miller and Panosian, 1997). A 
similar patient who was treated with oral artemether for 5 days has experienced tremor of the 
hand and gait disturbance (Elias et al., 1999). Consequently the artemisinin derivatives were 
implicated as cause of neurotoxic effects from these clinical observations.  
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Some detailed clinical and audiologic examinations were conducted aimed at evaluating 
neurotoxic effects of artemisinin derivatives to the auditory and vestibular pathways. One of such 
studies, a retrospective case-control study on 79 cases who had been treated with  > 2 courses of 
oral artesunate or artemether or in combination within the previous 3 years for uncomplicated 
falciparum malaria and 79 age and sex matched controls never having received artemisinin 
derivative was conducted in western Thailand. Clinical assessments were performed including 
Romberg’s test, gait and balance, fine finger dexterity, tuning fork for hearing acuity, eye 
movements, nystagmus, and behavior abnormality. Audiometry test was done for each individual 
at frequencies, 0.25 kHz, 0.5 kHz, 0.75 kHz, 1.0 kHz, 1.5 kHz, 2.0 kHz, 3.0 kHz, 4.0 kHz, 6.0 
kHz, and 8.0 kHz. Brainstem evoked response audiometry (BERA) test was performed for both 
ears to measure latencies at wave forms I-V representing the auditory pathways: Cochlea and 
acoustic nerve (I), medulla (II), caudal pons (III), rostral pons (IV), and mid brain (V). The test 
results showed no differences between the cases and controls. No neurotoxicity was identified 
due to the oral artesunate or artemether treatments (van Vugt et al., 2000). A similar case-control 
study along Thailand-Myanmar border was conducted in 68 subjects who had been treated with 
AL only at least once for uncomplicated falciparum malaria within the previous five years and 
68 age and sex matched controls never having received AL. A series of audiologic examinations, 
typanometry, audiometry and auditory brainstem response (ABR) were performed for each 
subject. The results showed no differences between cases and controls and no evidence of 
brainstem toxicity (Hutagalung et al., 2006). Nevertheless these retrospective studies had 
limitations to an unambiguously demonstrate neurotoxic effects of the artemisinins. First of all 
due to a lack of baseline assessment of the cases, as a result any consistent pre- and post-
treatment differences could not be evaluated and also any transient toxicity would have been 
missed.        
 
A follow-up or prospective case-control study was conducted to evaluate the ototoxicity of 
artemether-lumefantrine (AL) among construction site workers in Mozambique. The subjects 
were 150 cases who acquired uncomplicated falciparum malaria during their term of 
employment and treated with oral AL and 150 age-, gender-, weight-, ethnic matched control 
workers being AL-naive. All the subjects were evaluated with physical examinations and 
audiometry tests at the time of employment that is before AL treatment and at termination of 
their job contract. The mean interval from AL treatment to the final audiometry test was 163.8  
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day (range 3-392) for the cases. The audiometry tests are done at frequencies 0.25 kHz, 0.5 kHz, 
1.0 kHz, 2.0 kHz, 3.0 kHz, 4.0 kHz, 6.0 kHz, 8 kHz, but no other auditory evaluations were used  
to investigate neurotoxicity. It was reported that there was significant hearing loss in AL treated 
group at all frequencies of the audiometry test except for 0.25 kHz and 0.5 kHz. Hence AL was 
considered ototoxic, which could have been considered irreversible because the mean interval 
from drug exposure to final audiometry measurement was 163.8 day (Toovey and Jamieson, 
2004). However, the impact of noise at the construction site could not be ruled out as a 
confounding factor for the changes in the thresholds of hearing levels. On the other hand, the 
methods used to evaluate the neuro-ototoxicity are not comprehensive; such as lack of 
TEOAE/DPOAE, BERA, in order to evaluate auditory and vestibular pathways to demonstrate 
where the ototoxicity problem lies.  
 
6.  Aim of the Thesis  
The aim of the study was to address the controversial reports concerning the neuro-ototoxic 
effects of artemisinin based treatments of falciparum malaria patients whether it is transient or 
irreversible. Therefore, we conducted a prospective controlled randomized trial by comparing 
AL to Q and AP among uncomplicated falciparum malaria patients with detailed clinical 
examinations and comprehensive auditory and vestibular systems evaluation (using TEOAE, 
DPOAE, BERA, and Audiogram).  
 
The other purpose of the study was to evaluate and compare the efficacy and general tolerability 
of the study antimalarials and investigate underlying molecular markers correlated to drug 
resistance among the parasite isolates. Important parameters were possible side effects, treatment 
failure rate, clearance time, gametocyte clearance and detection of described and new point 
mutations in the drug-associated target genes. 
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7.  Overview of Study Outcomes 
 
7.1. Review of Antimalarials Tolerability and Ototoxicity Study 
Due to high degree and widespread resistance to the previously used first-line drug, 
sulphadoxine-pyrimethamine, for uncomplicated falciparum malaria, Ethiopia adopted 
artemisinin-based combination therapy (ACT) in 2004 in the form of Artemether-Lumefantrine 
(AL). During the broad introduction of the drug in 2006, we designed and conducted a 
prospective open-label randomized trial to assess tolerability and address the controversial 
reports concerning neuro-ototoxicity and resulting hearing loss due to AL by comparing it to 
Quinine (Q) and Atovaquone-Proguanil (AP) as “positive control” and “negative control”, 
respectively, in the treatment of uncomplicated falciparum malaria. A total of 230 patients > 5 
years of age were screened; those eligible after complete baseline audio-vestibular evaluations 
and with microscopy-confirmed uncomplicated falciparum malaria were recruited from April to 
August 2006 in Jimma University Hospital. Then 97 patients were randomized to receive either 
AL (n=30) or Q (n=35) or AP (n=32). Tolerability assessments and comprehensive audio-
vestibular evaluations were also performed after chemotherapy on follow-up days 7, 28, and 90 
for investigation of transient or irreversible adverse effects and ototoxicity. Clinical assessments 
included otoscopy, Rinne, and Weber tests; neurological examinations (Romberg, Unterberger’s 
stepping, gait, finger-to-nose, nystagmus, Halmagyi test); neuro-otologic evaluation was 
performed by transitory evoked otoacoustic emissions (TEOAE), distortion product otoacoustic 
emissions (DPOAE), pure tone audiometry (PTA), and brainstem evoked response audiometry 
(BERA).  
 
Tolerability was good; no serious adverse effects were observed related to the drugs upon 
malaria treatment, no vomiting occurred after ingestion of the antimalarial drugs and as a result 
patient compliance was efficient. However, hearing problems and tinnitus were more common 
on day 7 with nine of thirty patients complaining of hearing problems in the Q group. In seven of 
these, audiometry and OAE testing confirmed significant hearing loss. Few patients reporting 
subjective hearing impairment in the AL group did not have abnormal hearing test results. In the 
AP group, one patient complained of hearing problem on day 90 that corresponded to 
significantly impaired audiometry and OAE results; in this patient malaria reinfection was  
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diagnosed. PTA air conduction hearing thresholds were compared for a standard range of 
frequencies at 0.125 kHz, 0.25 kHz, 0.5 kHz, 1 kHz, 2 kHz, 3 kHz, 4 kHz, 6 kHz and 8 kHz. 
Bone conduction thresholds were also measured by PTA at all time points in order to exclude a 
possible conductive hearing loss. In the Q group, a hearing loss affecting all frequencies was 
evident on day 7 and has disappeared by day 28. Otherwise, no significant changes of the mean 
hearing thresholds compared to day 0 were evident. When comparing the mean 4-tone-average 
(0.5, 1, 2, 3 kHz) as the clinically most significant frequency range, a similar picture emerges. 
Multivariate analysis of the 4-tone-average revealed a strong interaction between the treatment 
groups and time on day 7, confirming the temporary threshold shift caused by quinine. 
Multivariate analysis of the mean average of higher frequencies (4, 6 and 8 kHz) reveals the 
same effect. There was no evidence of persistent hearing loss in any treatment group from the 
PTA results. The average DPOAE threshold level of the Q group on day 7 is markedly elevated 
from baseline, supporting the pure tone audiometry data. Multivariate analysis reveals a 
significant effect of time on the DPOAE threshold level changes for day 7 and day 28 in the 
three treatment groups that clearly depicts quinine ototoxicity on day 7. In addition transitory 
evoked otoacoustic emissions (TEOAE) could be elicited on both ears in all examinations, 
except for three patients in the Q group on day 7 who suffered a transient hearing loss greater 
than 30 dB. BERA interpeak latencies (IPL) were calculated for the I–V, I–III and III–V 
intervals. In all groups, IPL I–V was shorter on day 0 than on later time points of the follow-up, 
which is described to be impact of fever at the recruitment. The difference in IPL I–III between 
the AL group and the other two groups on day 28 was limited to the right ear. However, only one 
patient in the AL group had a potentially clinically relevant  interaural difference of IPL I–III 
greater than 10% on day 28, which disappeared by day 90. In another case IPL III–V was 
prolonged in one Q treated patient (for left ear) on day 28, but not on day 90. Therefore, no 
permanent drug-related prolongation of interpeak latencies occurred in all treatment groups.  
 
In conclusion, no neuro-ototoxicity was detected in the auditory and vestibular system of the 
patients due to AL. No hearing loss was observed in this study except the apparent transient 
quinine induced cochlear hearing loss due to temporary outer hair cell impairment detected by 
DPOAE. There are no serious adverse effects caused by the antimalarial drugs. Therefore, the 
standard oral AL regimen is safe and tolerable for the treatment of uncomplicated falciparum 
malaria.   
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7.2 Review of Antimalarials Efficacy and Molecular Markers Study 
Patients were examined clinically and parasitologically for uncomplicated falciparum malaria at 
recruitment and then treated with either Artemether-Lumefantrine [ fixed dose of 20 mg  
artemether/120 mg lumefantrine (children 5–14 kg bwt) or 40 mg/240 mg (children 15–24 kg 
bwt.) or 60 mg/360 mg (children 25–34 kg bwt.) or 80 mg/480 mg (adults and children ≥35 kg 
bwt.), at hrs. 0, 8, 24, 36, 48 and 60 (6 doses) ] or Quinine sulfate [10 mg/kg (children) or 600 
mg (adults and children ≥50 kg bwt.), three times daily for 7 days (21 doses) ]  or Atovaquone-
Proguanil [ 20 mg of atovaquone/8 mg of proguanil/kg (children < 40 kg bwt.) or 1000 mg/400 
mg (adults and children ≥40 kg bwt.) per day for 3 days (3 doses) ].    Blood samples were 
obtained at days 0, 7 and 28 as well as on any day until day 90 in case of re-occurrence of 
symptoms suggesting malaria and aliquots of 10 μl of capillary blood were spotted to Whatman 
3 MM Chromatographic filter paper, air dried and stored at ambient temperature for molecular 
analysis. Parasite DNA was extracted from blood spots on the filter paper by the Chelex method. 
Parasite species was determined by nested polymerase chain reaction (PCR). Genotyping of 
parasite isolates was done by restriction enzymes (RFLP) molecular analysis of msp-1 and msp-2 
genes to determine clonality and to distinguish between reinfection and recrudescence 
(resistance).  Molecular markers associated with drug resistance were determined by sequencing 
of pfserca and pfcytb genes; and by amplification and enzyme digestion of pfmdr1 and pfdhfr 
genes. 
 
In general there was adequate clinical and parasitological response of all the treatments by day 7, 
except for few patients having headache in all groups. No early treatment failure occurred in any 
drug group, but late treatment failures or recrudescences occurred on days ranging from 24 to 70. 
In the Q group (n=4, 11.4%; on day 24, 28, 28, 40) and AP group (n=2, 6.3%; on day 28, 28). In 
the AL group, one possible recrudescence (n=1, 3.3%; on day 70) was detected which was 
further confirmed by sequencing of msp-1 gene. Rate of gametocyte clearance from the 
peripheral blood was very fast and efficient with AL compared to the other drugs. The 
investigation of the molecular markers that are correlated to drug resistance showed a high 
prevalence of pfmdr1 mutation at codon 86Y, among 84.5% of the isolates in all treatment 
groups including the four recrudescent strains in the Q group. There was also high prevalence of 
polymorphisms at codons N51I (98.8%), C59R (87.6%), S108N (100.0%) of the pfdhfr gene,  
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these triple mutations occurred together in 83.3% of the isolates. Both recrudescent strains in the 
AP group showed the triple mutations (51I, 59R, 108N). The A16V mutation was only found in 
one of the recrudescent isolates in the AP group presenting as clinical symptomatic treatment 
failure. No mutations were detected in the amplified regions of the pfcytb gene of those two 
recrudescent strains in the AP group. The pfserca gene was amplified and sequenced from the 
codons 230 to 463 and 600 to 790 for isolates in AL group. There were twelve SNPs detected in 
the pfserca gene of the AL treatment group, six new and six previously described mutations, but 
all the carrier strains were treatment-sensitive. The previously reported E431K mutant codon was 
the most frequent, occurring in seven isolates. Each of the other mutations was detected only 
once. No sample showed more than two mutations. The previously described mutant codon 
S769N being associated with in vitro resistance in French Guiana was found in treatment 
sensitive isolate. Other recently published mutations in the pfserca gene were not detected in the 
amplified and sequenced regions of the gene in the isolates. The strain from day 70 
recrudescence yielded no mutation in the amplified region. The high degree of mutations 
observed in the pfmdr1 and pfdhfr are reminiscent of the impact of previously used first-line 
antimalarials chloroquine and sulphadoxine-pyrimethamine in this area. Those mutations in the 
Pfserca gene are observed in AL sensitive isolates and are considered to have spontaneously 
developed without resistance-conferring drug pressure. Overall, the distribution of these 
mutations does not indicate direct correlation of the markers with efficacy/resistance outcomes. 
However, they may serve as baseline information for further allelic selection that may happen 
due to long-term use of AL in this area.  
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Abstract
Background: Due to increasing drug resistance, artemisinin-based combination chemotherapy (ACT) has
become the first-line treatment of falciparum malaria in many endemic countries. However, irreversible
ototoxicity associated with artemether/lumefantrine (AL) has been reported recently and suggested to be
a serious limitation in the use of ACT. The aim of the study was to compare ototoxicity, tolerability, and
efficacy of ACT with that of quinine and atovaquone/proguanil in the treatment of uncomplicated
falciparum malaria.
Methods: Ninety-seven patients in south-west Ethiopia with slide-confirmed malaria were randomly
assigned to receive either artemether/lumefantrine or quinine or atovaquone/proguanil and followed-up
for 90 days. Comprehensive audiovestibular testing by pure tone audiometry (PTA), transitory evoked
(TE) and distortion product (DP) otoacoustic emissions (OAE) and brain stem evoked response
audiometry (BERA) was done before enrolment and after seven, 28 and 90 days.
Results: PTA and DP-OAE levels revealed transient significant cochlear hearing loss in patients treated
with quinine but not in those treated with artemether/lumefantrine or atovaquone/proguanil. TE-OAE
could be elicited in all examinations, except for three patients in the Q group on day 7, who suffered a
transient hearing loss greater than 30 dB. There was no evidence of drug-induced brain stem lesions by
BERA measurements.
Conclusion: There was no detrimental effect of a standard oral regimen of artemether/lumefantrine on
peripheral hearing or brainstem auditory pathways in patients with uncomplicated falciparum malaria. In
contrast, transient hearing loss is common after quinine therapy and due to temporary outer hair cell
dysfunction.
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Resistance to antimalarial drugs is a common challenge in
malaria endemic areas worldwide. Due to increasing
resistance of Plasmodium falciparum strains against chloro-
quine and sulphadoxine/pyrimethamine, several Asian
and African countries have changed their national policy
towards first-line treatment with artemisinin-based com-
bination chemotherapies (ACT) as recommended by cur-
rent WHO guidelines [1,2].
Some case reports [3,4] as well as a recent alarming report
on the possibility of irreversible ototoxicity of artemether/
lumefantrine in a retrospective evaluation of construction
site workers in Mozambique [5] have raised concerns that
this potentially serious side effect of ACT has not been
addressed thoroughly enough, although no evidence of
neurological side effects or ototoxicity has been observed
in human safety studies or large-scale field trials [6] and
case control studies [7-9].
Ototoxicity has been reported in association with the use
of quinoline type antimalarials [10,11], and quinine since
long is known to cause reversible hearing loss and tinni-
tus[12]. Ototoxic effects have not been reported with the
use of some other antimalarials in current use, such as
atovaquone/proguanil.
To clarify the question of artemisinin-induced hearing
loss, this study integrated a comprehensive neuro-oto-
logic assessment into an investigator-initiated, open-
label, randomized, controlled study to compare arte-
mether/lumefantrine with quinine and atovaquone/pro-
guanil in the treatment of uncomplicated falciparum
malaria.
Methods
Study area and population
The study was carried out at Jimma University (JU) Hos-
pital in the city of Jimma, 1,700 m above sea level and 335
km south west of Addis Ababa, Ethiopia. In this region,
malaria transmission is seasonal with peaks from April to
June and from September to December during and after
the rainy seasons [13]. The first-line treatment of uncom-
plicated falciparum malaria changed from sulphadoxine/
pyrimethamine to AL in Ethiopia in 2004 [14]. Since the
drug has not yet been available until recently, oral quinine
has mainly been used instead.
Patients over five years of age and suitable for complete
audiovestibular testing with parasitologically proven
uncomplicated falciparum malaria were recruited from
April until August 2006. Uncomplicated falciparum
malaria was defined as asexual parasitaemia of less than
100,000/μl blood, acute fever or a history of fever within
the preceding 24 hours, and no signs or symptoms sug-
gesting complicated or severe malaria as defined by WHO
[15]. Patients with significant hearing loss as determined
by failure to detect transitory evoked otoacoustic emis-
sions in either ear, intake of anti-malarial treatment
within the previous seven days, severe underlying condi-
tions or concomitant disease masking assessment of
response, history of allergy or intolerance against study
medications, or pregnancy were excluded. Audiometric
testing (duration 1–1.5 h) of eligible patients at enrol-
ment was completed before starting antimalarial treat-
ment.
The study was approved by the Ethical Committee of
Jimma University, Ethiopia. Written informed consent
was obtained from each patient or the parental guide. Per-
sonal subject data are kept confidential. The trial is regis-
tered with ClinicalTrials.gov, number NCT00451139. The
recommendations guiding physicians in biomedical
research involving human subjects issued by the World
Medical Association Declaration of Helsinki (Edinburgh,
2000) were applied to this project.
Antimalarial drug regimens
Eligible patients were consecutively stratified according to
gender and age and assigned to one of the following treat-
ment groups by stratified random sampling:
1. Artemether/lumefantrine (AL): 20 mg of artemether
and 120 mg of lumefantrine (children 5–14 kg bwt.) or 40
mg/240 mg (children 15–24 kg bwt.) or 60 mg/360 mg
(children 25–34 kg bwt.) or 80 mg/480 mg (adults and
children ≥35 kg bwt.), at hrs. 0, 8, 24, 36, 48 and 60 (6
doses). Patients were instructed to take the doses with
high fat food.
2. Quinine sulphate (Q): 10 mg/kg (children) or 600 mg
(adults and children ≥50 kg bwt.), according to about 8
mg/kg Quinine base, three times daily for 7 days (21
doses).
3. Atovaquone/proguanil (AP): 20 mg/8 mg/kg (children
< 40 kg bwt.) or 1000 mg/400 mg (adults and children
≥40 kg bwt.) per day for 3 days (3 doses).
Artemether/lumefantrine 20/120 mg tablets (Coartem®,
Novartis, manifactured by Bejing Novartis Pharma Ltd,
Bejing China) and quinine sulphate 300 mg tablets
(Remedica Ltd, Limassol-Cyprus-Europe) were obtained
from the Ethiopian governmental drug programme
through the JU hospital pharmacy. Blister packs of
atovaquone/proguanil (Malarone®) were purchased from
GSK, Germany.Page 2 of 12
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Patients were treated on an outpatient basis and returned
on day 7, 28 and 90 and on any day during the follow-up
period if symptoms returned. Clinical reassessments cov-
ered assessments for potential treatment failure and for
potential adverse reactions to the treatment drug includ-
ing complete audiovestibular testing.
Finger prick blood samples were taken at day 0 for confir-
mation of P. falciparum mono-infection and calculation of
parasitaemia (parasites per 200 white blood cells, calcula-
tion based on an assumed mean WBC count of 8,000/ml)
by microscopic assessment of Giemsa-stained thick and
thin blood smears. Aliquots of 10 μl of capillary blood
were spotted to Whatman 3 MM Chr filter paper, air dried,
and stored at ambient temperature for later molecular
analysis. Follow-up blood samples were obtained at days
7 and 28 as well as on any day of potential clinical treat-
ment failure. Patients with falciparum or vivax malaria
during the follow-up period were treated according to
national guidelines [14]. These patients were excluded
from the study after treatment. Patients who completed
examinations on day 28 were included in the audiovestib-
ular analysis.
Audiovestibular tests were performed by an examiner
blinded to treatment allocation in a separate building spe-
cifically designated for this purpose. Although a sound-
proof chamber was not available, care was taken to reduce
ambient noise to a minimum (see below). Clinical audio-
vestibular evaluation at each visit included the history of
specific complaints (i.e., hearing loss, otalgia, tinnitus,
vertigo), otoscopy, Weber and Rinne tests, examination
for spontaneous and head-shaking nystagmus under Fren-
zel glasses, and testing the vestibular function by rapid
passive head rotation. Physical examination included gait,
Romberg and Unterberger test, finger-to-finger test, and
hand rapid alternating movements [16].
Pure tone audiometry was performed with a Madsen
Midimate 622D diagnostic audiometer (GN Otometrics,
Copenhagen, Denmark) and Beyer DT 48 headphones.
The thresholds for frequencies from 125 to 8000 Hz were
determined via air conduction. In addition, bone conduc-
tion thresholds for 250 to 6000 Hz were determined in
order to exclude conductive hearing loss.
In contrast to conventional audiometry, the detection of
otoacoustic emissions does not rely on the patients coop-
eration, and is an excellent indicator for physiologic inner
ear function. Transitory evoked (TE) and distortion prod-
uct (DP) otoacoustic emissions (OAE) were measured
with a Cochlea Scan® device (Fischer Zoth, Germering,
Germany). TEOAE were analysed using a screening proto-
col giving a pass (detectable TEOAE) vs. fail result.
DPOAE levels were measured at frequencies of f2 = 1.5, 2,
3, 4, 6 kHz with at least three different primary tone levels
per frequency between 15 and 65 dB (f2/f1 = 1.2). From
the resulting DPOAE growth functions, DP thresholds
and estimated hearing thresholds are calculated based on
normative data [17,18]. The average noise floor during
measurements was -1.2/-2.6/-4.1/-3.6/-3.5 dB for 1.5/2/
3/4/6 kHz.
Brain stem evoked response audiometry (BERA) examines
the velocity of nerve signal conduction along the auditory
pathways from the cochlea to the brainstem, and is the
gold standard for detection of damage to the participating
neural structures. The measurements were done using an
evoselect system (Pilot Blankenfelde, Blankenfelde, Ger-
many). The stimulus, a click of alternating polarity, was
delivered at a rate of 11.1 Hz at a level of 80 dB HL and
contralateral masking at 40 dB HL to patients resting in a
supine position. 2000 measurements were averaged and
the absolute and interpeak latencies of Jewett waves I, III
and V determined.
For molecular typing sample DNA was extracted from fil-
ter paper bloodspots using Chelexò (Bio-Rad, Germany)
as described elsewhere [19]. Parasite species was con-
firmed by nested polymerase chain reaction (PCR) [20].
Sequences of parasite genes coding for the polymorphic
merozoite surface proteins (MSP) 1 and 2 were amplified
by nested PCR and analysed by restriction fragment length
polymorphisms (RFLP) technique [21,22]. MSP1 and
MSP2 fragment patterns of isolates from patients with
parasite re-appearance were compared with those of the
respective recruitment isolates to distinguish recrudes-
cences from new infections [23].
Statistical analysis
A sample size of 23 in each group was calculated to have
90% power to detect a difference in means of 5.0 dB (e.g.,
the difference between a group 1 mean of 5.0 and a group
2 mean of 0.0) assuming that the common standard devi-
ation is 5.0 dB using a two group t-test with a 0.05 two-
sided significance level. In order to avoid problems with
the assumption of normal distribution and to compensate
for possible drop-outs it was decided to increase the sam-
ple size to at least 30 per group. Data were analysed using
SSPS 14.0 software for descriptive statistical analyses and
R package V2.4.0 for multivariate methods. The baseline
characteristics of the patients were compared by Kruskal-
Wallis test for variables that are measured on a continuous
scale or by Pearson Chi-square test for categorial variables.
The audiological data in a longitudinal setting were fitted
in mixed linear model approaches. Potential factors
included in the models were day after enrolment, therapy
group and side. Variables not significant on the 5% level
were sequentially eliminated from the models with excep-Page 3 of 12
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and right side showed no significant differences, both val-
ues were treated in the models as repeating measure-
ments. Generally, a p value of < 0.05 was considered
significant.
Results
230 patients with suspected malaria were screened and
133 were excluded for various reasons (Figure 1). 97
patients were included and randomized. 30 patients
received AL, 35 Q, and 32 AP (Figure 1). Baseline charac-
teristics are given in Table 1. None of the patients had
received an artemisinin compound before. Cumulated
numbers of patients lost to follow-up were one at day 7,
four at day 28, and seven at day 90. Thirteen patients were
excluded due to recrudescence or new infection (Figure 1).
patient flow chartFigure 1
patient flow chart. Enrollment, randomization and follow-up of the patients. § The reasons for exclusion (number of 
patients) were ear discharge (20), impacted ear wax (18), repeated previous otitis media (14), perforated ear drum (6), nega-
tive TEOAE recording (15), Weber test lateralized (10), self-treatment with chloroquine (18), mixed infection (17), pregnancy 
(15). * Patients treated with a second course of antimalarials because of recrudescence or new infection were excluded from 
audiovestibular evaluation.Page 4 of 12
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Table 1: Baseline characteristics of the patients who reached the primary end-point (day 28)
Quinine Atovaquone/Proguanil Artemether/Lumefantrine
n 30 30 30
sex m/f 16/14 16/14 18/12
age range 6 – 50 6 – 35 8 – 40
mean 19.2 19.9 18.1
median 16 18 17
Temperature (C°) range 36.0 – 39.5 36.0 – 39.3 35.6 – 39.9
mean 37.4 37.3 37.5
median 37.2 37.3 37.4
Parasitaemia range 360 – 63,000 400 – 69,880 480 – 83,600
mean 15,469 13,028 21,189
median 6,740 4,960 9,300
Symptoms Headache 30 30 30
Nausea/vomiting 21 17 22
Shivering 23 26 21
Diarrhea 4 2 3
Actual daily dose (mg/kg) range 30.5 – 36 15 – 23 2.3 – 4.6
mean 34.9 19.5 3.4
stdev 1.6 1.9 0.6
Baseline patients' characteristics of the patients who reached the primary end-point (day 28) were not significantly different between the three 
treatment groups in respect to age (Kruskal-Wallis-test, p = 0,504), sex (χ2-test, p = 0,835), parasitaemia (Kruskal-Wallis-test, p = 0,444), body 
temperature (Kruskal-Wallis-test, p = 0,860). There is also no significant difference in these baseline characteristics of the treatment groups when 
comparing all 97 treated patients.
Table 2: Clinical and parasitological efficacy
PCR-corrected failure rates A/L Quinine A/P
Clinical failure rate day 7 0/30 0/35 0/32
Parasitological failure rate day 7 0/30 0/35 0/32
Intention to treat failure rate* day 7 0/30 1/35 (~3%) 0/32
Clinical failure rate day 28 0/30 3/35 (~9%) 1/32 (~3%)
Parasitological failure rate day 28 0/30 3/35 (~9%) 2/32 (~6%)
Intention to treat failure rate* day 28 0/30 7/35 (~20%) 4/32 (~13%)
Recurrent parasitaemia
Number of patients with recrudescence** (day) 1 (70) 4 (24, 28, 28, 40***) 2 (28, 28)
Number of patients with new infection** (day) 1 (73) 4 (34, 40, 40***, 65) 1 (80)
Number of patients with P. vivax infection (day) 2 (28, 28) 5 (22, 25, 27, 28, 28) 2 (28, 28)
Gametocytaemia
Number of patients on day 0 1 3 1
Number of patients on day 7 2 10 16
Number of patients on day 28 0 2 0
* lost to follow-up included
**P. falciparum: Genotyping by PCR and RFLP patterns of the MSP-1 and MSP-2 gene
*** One sample showed two different clones on day 40, one of them corresponded to the clone on day 0.
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On day 7 no treatment failure was detected in any group
(Table 2). Until day 28, three patients in the Q group and
one in the AP group presented with falciparum malaria.
Another patient with asymptomatic parasitaemia was
identified in the AP group. The parasitological failure rate
on day 28 was 9% and 6% in the Q and AP group, respec-
tively. There was no treatment failure in the AL group. All
treatment failures were recrudescences as confirmed by
genotyping.
Between day 28 and day 90 seven patients with falci-
parum malaria were diagnosed. Five patients had a new
infection. A recrudescent and a new strain were found in a
patient in the Q group on day 40, and one recrudescence
occurred on day 70 in the AL group.
Nine patients (five treated with Q, two with AP, and two
with AL) showed P. vivax infection during follow-up
(Table 2).
Tolerability and ototoxicity assessment
No vomiting occurred after ingestion of the antimalarial
drugs, and no serious adverse events were reported during
treatment and follow-up. Most symptoms present at the
time of diagnosis resolved until day 7 (Table 3). However,
hearing problems and tinnitus were more common on
day 7 with nine of thirty patients complaining of hearing
problems in the Q group. In seven of these, audiometry
and OAE testing confirmed significant hearing loss.
Patients reporting subjective hearing impairment in the
AL group did not have abnormal hearing test results. In
the AP group, only the reported hearing loss by one
patient on day 90 corresponded to significantly impaired
audiometry and OAE results; in this patient malaria rein-
fection was diagnosed.
Pure tone audiometry
Air conduction hearing thresholds were compared for a
standard range of frequencies from 0.125 to 8 kHz. Bone
conduction thresholds were also measured at all time
points in order to exclude a possible conductive hearing
loss. Figure 2 shows similar mean hearing levels at day 0
(baseline) for all groups and all frequencies. In the Q
group, a hearing loss affecting all frequencies is evident on
day 7 and has disappeared by day 28. Otherwise, no sig-
nificant changes of the mean hearing thresholds com-
pared to day 0 were evident, except for some slight general
improvement in all groups.
When comparing the mean 4-tone-average (0.5, 1, 2, 3
kHz) as the clinically most significant frequency range, a
similar picture emerges (Figure 3). Multivariate analysis of
the 4-tone-average revealed a strong interaction between
the factors group and time on day 7, confirming the tem-
porary threshold shift caused by quinine. Multivariate
analysis of the mean average of higher frequencies (4, 6
and 8 kHz) reveals the same effect.
Table 3: Symptoms and clinical signs
Drug Group Quinine Atovaquone-proguanil Artemether-lumefantrine
n = 30 30 30 23 30 30 30 26 30 30 30 28
day 0 7 28 90 0 7 28 90 0 7 28 90
Hearing Problem 0 9 1 0 0 1 0 1 1 2 1 0
Tinnitus 2 8 3 0 4 6 1 1 6 4 2 0
Vertigo 6 0 1 0 8 1 0 0 4 3 1 0
Imbalance 1 0 0 0 0 0 0 0 0 0 0 0
Spontaneous nystagmus 0 0 0 0 0 0 0 0 0 0 0 0
Provoked nystagmus 0 0 0 0 0 0 0 0 0 0 0 0
Pathologic head rotation test 1 0 0 0 0 0 0 0 1 0 0 0
Impaired coordination 0 0 0 0 0 0 0 0 0 0 0 0
Fever 24 0 5 2 23 2 3 1 26 0 1 2
Shivering 23 0 1 2 26 4 3 1 21 1 1 1
Headache 30 5 5 2 30 10 6 3 30 7 4 2
Nausea 21 1 2 0 17 1 1 0 22 0 0 4
Diarrhea 4 0 0 0 2 1 1 0 3 0 0 0
Vomiting 1 0 0 0 1 0 0 0 1 0 0 0
Anorexia 2 0 1 0 3 0 0 0 0 0 0 0
Abdominal pain 1 0 0 0 0 0 0 0 1 0 0 0
Arthralgia 3 0 0 0 3 0 0 0 1 0 0 0
Myalgia 1 0 0 0 0 0 0 0 0 0 0 0
Chest pain 0 0 0 0 0 1 0 0 0 0 0 0
Cough 0 1 0 0 0 1 0 0 0 0 0 0Page 6 of 12
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was no evidence of persistent hearing loss in any treat-
ment group.
Otoacoustic emissions
The average DP threshold level of the Q group on day 7 is
markedly elevated from baseline, corroborating the pure
tone audiometry data (Figure 4). Multivariate analysis
reveals a significant effect of time on the DP threshold lev-
els for day 7 and day 28. This is reflected in the general
improvement of DP thresholds for these time points
when compared to baseline. The three treatment groups
do not behave differently, except on day 7 when a signifi-
cant combined effect of time and group is visible as the Q
ototoxicity.
Transitory evoked otoacoustic emissions (TEOAE) could
be elicited on both ears in all examinations, except for
three patients in the Q group on day 7, in whom TEOAE
could not be detected in either ear, and who suffered a
transient hearing loss greater than 30 dB.
Brainstem evoked response audiometry
Interpeak latencies (IPL) were calculated for the I–V, I–III
and III–V intervals. In all groups, IPL I–V were shorter on
day 0 than on later time points (Figure 5). The difference
in IPL I–III between the AL group and the other two
groups on day 28 was limited to the right ear. However,
only one patient in the AL group had a potentially clini-
cally relevant interaural difference of IPL I–III greater than
10% on day 28, which disappeared by day 90. No perma-
nent drug-related prolongation of interpeak latencies
occurred.
By comparison of these measurements with normative
data (2.49 ms for IPL I–III, 2.16 ms for IPL III–V, 4.45 ms
for IPL I–V; [25] ), IPL III–V was prolonged in one Q
treated patient (left ear) on day 28, but not on day 90.
pure tone hearing levelsFigure 2
pure tone hearing levels. Audiometrically determined mean hearing levels on day 0, 7, 28 and 90. Transient hearing loss in 
the quinine treated group is observed on day 7. No permanent hearing loss in either group occurred. Measuring unit of y-axis 
is dB nHL.
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The controversy about artemisinins and ototoxicity in
humans has only recently been investigated by Toovey et
al [5]. The authors compared audiometric data from 150
adult construction site employees who have been treated
with AL for uncomplicated malaria with 150 matched
controls who neither suffered malaria nor received arte-
mether. Significant hearing loss over the term of their
employment was found in frequencies between 1 and 8
kHz. This was judged to be irreversible, because the time
between treatment and exit audiogram (mean = 163 days,
range 3–392 days) did not correlate with the degree of
hearing loss [26]. However, possible confounding factors
like the influence of noise exposure in these construction
site workers or the lack of a control group of malaria
patients treated with other antimalarials, make it difficult
to establish a causal relationship between hearing loss
and AL therapy from this retrospective evaluation.
Animal studies demonstrated that parenteral admininis-
tration of lipophilic artemisinin derivatives – such as arte-
mether – can induce focal brainstem lesions including
auditory and vestibular pathways (reviewed in [27] ). Oral
preparations, however, have different pharmacokinetics
and do not achieve as high plasma concentrations [28],
suggesting that the prolonged presence of artemisinin
upon slow release from oil-based intramuscular formula-
tions and the relatively high doses used in animal studies
are the main cause of neurotoxicity in laboratory animals.
A post-mortem study examined brains of patients who
had died of severe malaria and had received either intra-
muscular artemether (n = 6) or intravenous quinine (n =
15) in doses exceeding currently deployed regimens and
found no evidence of the typical artemisinin lesions
observed in animal studies [29]. However, since median
time from admission to death in the artemether group was
Pure tone average 0,5–3 kHzFigure 3
Pure tone average 0,5–3 kHz. Plot of means +/- 1 standard deviation of the pure tone average at 0.5, 1, 2, and 3 kHz for 
day 0, 7, 28 and 90 stratified by therapy group (solid line: Quinine, dashed line: Atovaquone/proguanil, dotted line: Artemether/
lumefantrine). As depicted in the graph a slight improvement of PTA was found during the first 28 days after treatment in the 
Atovaquone/proguanil and Artemether/lumefantrine group unlike the Quinine group, which experienced a marked but tran-
sient hearing loss measured on day 7. On day 90, the differences of means were larger than those on day 28, which can be 
explained as an effect of the long-term observation. No permanent hearing loss in either group occurred. The results pre-
sented in the graph are strongly confirmed by multivariate analysis. Measuring unit of y-axis is dB nHL.
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Malaria Journal 2008, 7:179 http://www.malariajournal.com/content/7/1/179only 76.5 h, delayed neurotoxicity may not have been
detected, as suggested from in vitro studies [30].
Detailed neurological data are provided by Price et al: of
more than 1,000 patients above five years of age treated
with artemether or artesunate (alone or in combination
with mefloquine) and examined on days 2, 7 and 28 post-
treatment, no patient developed deafness (assessed by
tuning-fork test) or permanent neurological abnormali-
ties.
A retrospective study carried out in Vietnam [8] compared
337 subjects who had received from two to 21 courses
(median = 2) of either artemisinin or artesunate with 108
controls from the same village. Even though 20% of the
subjects had received cumulative doses of ≥ 500 mg/kg
artemisinin (or the adjusted equivalent of artesunate),
which might be more than in any other group of people
in the world, the authors found no evidence of a drug
effect on screening audiometry (testing for hearing loss ≥
40 dB), brainstem evoked auditory potential latencies or
neurological examination. Similar results were obtained
in two case-control studies from Thailand in 79 subjects
treated at least twice with oral artesunate or artemether [9]
and in 68 patients who had been treated with AL [7].
A recent study in 15 adult volunteers with experimental
falciparum malaria treated with AL could not detect any
ototoxicity by using conventional and evoked response
audiometry, but did not compare artemisinins to other
antimalarials [31].
This study is the first randomized clinical trial directly
comparing ototoxicity of AL with other antimalarial
drugs. Quinine has since long been known to cause hear-
ing loss and tinnitus (cinchonism). Generally, this side-
effect is reported to be reversible within about 24 hours
[32], although some case reports have described perma-
nent hearing impairment associated with quinine treat-
ment. In guinea pigs given large doses of quinine, there is
degeneration of the organ of Corti which begins with loss
of the external hair cells, and may further affect the stria
vascularis and inner hair cells.
The Q and AP group can be viewed as a "positive control"
and "negative control", respectively. Furthermore, an
DPOAE level 1,5–6 kHzFigure 4
DPOAE level 1,5–6 kHz. Mean DPOAE estimated hearing levels +/- 1 standard deviation at 1.5, 2, 3, 4 and 6 kHz (solid line: 
Quinine, dashed line: Atovaquone/proguanil, dotted line: Artemether/lumefantrine). Estimated hearing levels are elevated in 
the quinine treated group on day 7. No permanent elevation in estimated hearing levels in either group occurred, which is con-
firmed by multivariate analysis. Measuring unit of y-axis is dB nHL.
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Interpeak latencies I–V, I–III, III–VFigur  5
Interpeak latencies I–V, I–III, III–V. Mean interpeak latencies between Jewett waves I, III and V +/- 1 standard deviation 
(solid line: Quinine, dashed line: Atovaquone/proguanil, dotted line: Artemether/lumefantrine). Interpeak latencies in all groups 
are shorter on day 0, when patients have elevated body temperature. The difference in IPL I–III between the Artemether/lume-
fantrine group and the other two groups is limited to the right ear. No permanent drug-related prolongation of interpeak 
latencies occurs, as confirmed by multivariate analysis.
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Malaria Journal 2008, 7:179 http://www.malariajournal.com/content/7/1/179attempt was made to evaluate the study population's
audiovestibular systems as comprehensively as possible,
including air and bone conduction audiometry for defi-
nite exclusion of conductive hearing loss and otoacoustic
emissions for direct objective assessment of cochlear func-
tion. In addition to the assessment on day 28, patients
were examined on a late time-point (day 90) to check for
reversibility of any potential hearing loss. In consequence,
day 90 data could be biased by the fact that not all patients
were available for the day 90 examinations (7 in the qui-
nine group, 4 in the AP group and 2 in the AL group).
However, a separate analysis including only patients who
completed follow-up until day 90 showed results similar
to those depicted.
The relatively low numbers of positive clinical findings or
complaints related to the audiovestibular system (Table
3) makes comparison across groups difficult. Neverthe-
less, the transient quinine ototoxicity on day 7 is clearly
correlated with an elevated number of patients complain-
ing of hearing problems. When comparing the time
course in the overall patient population, there is a rela-
tively high proportion of patients who complain of tinni-
tus on day 0 and of tinnitus and perceived hearing loss on
day 7. The symptom vertigo which is prevalent primarily
on day 0 does not seem to be of vestibular origin, since the
clinical vestibular function tests are not significantly
abnormal in either group. There were no relevant neuro-
logical impairments detected. For practical reasons, this
study did not incorporate objective vestibular function
tests. Rotatory and caloric vestibular tests necessitate a
considerable amount of specialized equipment. Vestibu-
lar evoked myogenic potentials (VEMP) recording is now
emerging as a reliable tool to assess otolith function and
could be useful in future studies, since this can be done
with a standard BERA equipment. The air conduction
hearing thresholds of our patients show no detrimental
influence of AL in comparison to the other two study
drugs. In contrast, a significant temporary hearing loss
was observed in quinine treated patients on day 7. The
observed general tendency of improved hearing levels on
later time points in comparison to day 0 could be due to
either a learning process or a direct transient negative
effect of malaria on hearing or a lack of concentration in
the acutely ill patients on day 0. The relatively high thresh-
olds in the lower frequencies probably reflect the presence
of some ambient noise.
Otoacoustic emissions are sound signals resulting from
the mechanical action of outer hair cells in the organ of
Corti. By stimulating the cochlea simultaneously with two
signals of specific frequencies and sound pressure levels,
distortion product otoacoustic emissions at a third spe-
cific frequency are elicited and can be measured. By plot-
ting stimulus (input) sound pressure levels versus DP
(output) levels, a DP threshold value can be calculated,
i.e. the lowest stimulus level producing an outer hair cell
response. Since outer hair cell responses are needed for
physiological hearing perception at the hearing threshold,
this DP threshold correlates very well with the subjective
hearing threshold. It, therefore, provides an objective esti-
mate of hearing levels in patients with mild to moderate
cochlear hearing loss [17].
Overall, the objective otoacoustic emission data largely
parallel the subjective audiometric data. It is therefore
demonstrated that the elevated hearing levels in audio-
metric measurements were due to the known transient
cochleotoxic effect of quinine.
DP thresholds of later time points are generally lower than
those on day 0 (except for the quinine group on day 7).
This cannot be due to a lack of concentration on day 0 nor
to a learning curve, since this test directly assesses outer
hair cell function without the need for patients' coopera-
tion. The fact that the DP threshold levels are slightly
lower than the pure tone audiometer thresholds is proba-
bly due to some ambient noise that could not be avoided
in lack of a truly sound-proof chamber.
From the pattern of artemisinin-induced focal brainstem
lesions in animal studies, it can be expected that an anal-
ogous lesion in humans would lead to a prolongation of
the interpeak latency of Jewett waves III–V. The observed
shorter interpeak latencies on day 0 are associated with
elevated body temperature, a correlation previously
described [33,34]. There was no permanent drug-related
latency prolongation in the patients treated with AL. A
prolonged interpeak or absolute latency, compared with
normative data, occurred in none of the AL-treated
patients.
Conclusion
In conclusion, this study could not detect any detrimental
effect of a standard oral regimen of AL on peripheral hear-
ing or brainstem auditory pathways in patients with
uncomplicated falciparum malaria as assessed by pure
tone audiometry, otoacoustic emission recording and
brainstem evoked response audiometry. In contrast, this
study clearly detects the transient quinine induced hearing
loss due to temporary outer hair cell dysfunction. These
results therefore support the continued use of oral artem-
isinine based combination therapy for uncomplicated
malaria.
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Abstract
Background: The emergence of drug resistance is a major problem in malaria control. Combination of molecular
genotyping and characterization of mutations or single nucleotide polymorphisms (SNPs) correlated with drug
resistance can provide information for subsequent surveillance of existing and developing drug resistance patterns.
The introduction of artemether/lumefantrine (AL) as first-line treatment, never used before in Ethiopia, allowed the
collection of baseline data of molecular polymorphisms before a selection due to AL could occur.
Method: 97 patients with uncomplicated falciparum malaria were recruited from April to June 2006 and treated
with either AL, quinine (Q) or atovaquone/proguanil (AP) in Jimma University Hospital, Ethiopia. Mutations or SNPs
associated with resistance to these drugs were analysed by RFLP (pfdhfr, pfmdr1) and sequencing of the target
genes (pfcytb, pfserca ).
Results: SNPs previously reported to be associated with resistance to the study drugs were identified in
recrudescent and treatment sensitive isolates. A total of seven recrudescences were obtained. The pfmdr1 N86Y
mutation was found in 84.5% of isolates. The triple mutation 51I,59R,108N of the pfdhfr gene occured in high
frequency (83.3%) but no pfcytb mutation was detected. Sequencing showed a variety of previously described and
new mutations in the pfserca gene.
Conclusion: The prevalence of mutations was in accordance with the expected patterns considering recent drug
regimens. The broad introduction of AL and the cessation of former drug regimens might probably change the
current distribution of polymorphisms, possibly leading to decreased sensitivity to AL in future. Continuous
surveillance of molecular patterns in this region is, therefore, recommended.
Background
Malaria is still one of the leading health problems in our
time. Most cases and deaths occur in Sub-Saharan
Africa. Malaria is endemic in large parts of Ethiopia
including the town of Jimma and its surroundings with
most cases occurring from September to December and
April to June during and after the rainy seasons [1].
High levels of drug resistance of Plasmodium falciparum
strains against anti-malarials, first chloroquine and later
sulphadoxine/pyrimethamine (SP), resulted in new drug
policies in Ethiopia. In 2004, the first-line treatment
recommendation was switched from SP to artemether-
lumefantrine (AL), an artemisinin-based combination
therapy (ACT) [1-3]. Due to a shortage in supply, Qui-
nine was used for several months instead. AL was intro-
duced by the underlying study in this region. ACT
combines the potential of rapid reduction of the parasite
burden and elimination of remaining parasites due to
longer-acting partner drugs [4]. The correlation between
distinct SNPs and anti-malarial drug resistance or clini-
cal outcome has been widely discussed. Mutations in
the Plasmodium falciparum multi-drug resistance
(pfmdr1) gene have been associated with resistance to
chloroquine, quinine, mefloquine, lumefantrine and
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artemisinin [5-8]. Increased sensitivity to (Dihydro-)
Artemisinin in the presence of wild type codon 86 in
pfmdr1 and in vivo selection of pfmdr 86N during AL
treatment has been reported [9-12].
The target structure for artemisinins was first
described by Eckstein et al in 2003, abandoning other
theories about the mode of action. PfATP6, a SERCA-
type ATPase (pfserca) of P. falciparum, is inhibited by
artemisinins [13]. An L263E replacement and other
mutations decreased sensitivity to artemisinins [14].
Since then, further resistance-related mutations con-
cerning artemisinins have been detected in laboratory
strains and field isolates associated with in vitro resis-
tance [15-17]. Recent reports about high in vivo toler-
ance of artemisinin-based combination therapy (ACT)
and artesunate monotherapy in Cambodia and Thailand
are all the more alarming [18-20].
In this study, polymorphisms related to drug resis-
tance were investigated. Mutations of the genes pfmdr1
(codon 86) and pfdhfr (codon 16, 51, 59, 108, 164), the
latter associated with proguanile resistance, were ana-
lyzed by RFLP. Regions in the pfserca and Plasmodium
falciparum cytochrome B (pfcytb) gene related to arte-
mether and atovaquone resistance, respectively, were
sequenced.
Methods
Study area and population
The study was performed at the Jimma University (JU)
Hospital in the city of Jimma, 1,700 m above sea level
and 335 km south west of Addis Ababa, Ethiopia.
Patients over five years of age (mean 19.1, range 6-50)
with parasitologically proven uncomplicated falciparum
malaria were recruited from April until June 2006. Writ-
ten consent was obtained from either the patient or a
parent/legal guardian. The study was conducted conco-
mitantly with the previous published work on ototoxicity
of artemether/lumefantrine in comparison with quinine
and atovaquone/proguanil and was approved by the
Jimma University Ethical Committee and is registered
with Clinical Trial.gov, Number NCT00451139 [21].
Procedures
Blood samples were obtained at days 0, 7 and 28 as well
as on any day until day 90 in case of re-occurrence of
symptoms suggesting malaria [22]. Aliquots of 10 μl of
capillary blood were spotted to Whatman 3 MM Chr fil-
ter paper, air dried, and stored at ambient temperature
for later molecular analysis. The definition of the treat-
ment outcome followed the WHO draft protocol for
areas with low or moderate malaria transmission [2].
Parasite DNA was extracted from blood spots on the
filter paper by the Chelex method [23]. The species was
identified by nested polymerase chain reaction (PCR)
[24]. Single and multiple clone infections from day 0
were determined by amplification of msp1 and msp2
genes. To distinguish between re-infection and recrudes-
cence, genotyping by amplification of msp1, msp2 and
enzymatic digestion (RFLP) of the PCR products was
performed between the pair of samples [25].
To amplify the pfmdr1 and pfdhfr gene, a nested PCR
was used, the polymorphisms were detected by RFLP
[26,27]. The PCR products were separated in 2% agarose
gels stained with ethidium bromide and visualized under
UV light. The regions of interest of the pfcytb and the
pfserca gene were amplified by established PCR proce-
dures [28,29]. The amplified gene fragments were puri-
fied from gel using Ultrafree-DNA extraction kit. Cycle
sequencing was done with the BigDye Terminator Cycle
Sequencing Kit and products analysed on the ABI3730
sequencer. Primers used for sequencing were those from
the PCR. Sequences were verified using templates from
two independent amplifications of the same DNA sam-
ple. Sequencing analysis was performed from both direc-
tions for each template. Sequences were analysed using
the programme Bioedit and the NCBI blast function for
comparison with sequences published in the GenBank
database. (Reference strain for pfserca: Dd2, accession
number: AB121053 and 3D7, acc no.: AL844501.1; for
pfcytb: 3D7, acc. No.: AF069605)
Results
97 patients were included in the study with 30 patients
receiving AL, 35 Q, and 32 AP. Clinical and parasitolo-
gical efficacy as well as baseline data were described
elsewhere in detail [21]. No treatment failure occured
before or on day 7 in any treatment group. Until day 28,
three patients in the Q group and two in the AP group
presented with PCR-confirmed recrudescent falciparum
malaria. Later, one recrudescence was detected in a
patient in the Q group on day 40, and possibly another
on day 70 in the AL group (Table 1).
The overall prevalence of pfmdr1 mutations was high
(84.5%) (Table 2). In the Q group, all four treatment
failures showed the pfmdr1 mutation at codon 86Y, but
also 90.0% of the clinical sensitive samples presented
with the mutation. In the AL group, four samples
showed the wild type, one mixed (wild type and muta-
tion); the remaining 25 samples exhibited only the
mutation.
The expected high prevalence of the polymorphisms
at codons 51I, 59R, and 108N of the pfdhfr gene was
found. Both recrudescent strains in the AP group
showed the triple mutations (51I, 59R, 108N). The only
A16V mutation in the AP group was found in the clini-
cal symptomatic treatment failure (Table 1).
The pfserca gene was amplified and sequenced from
the codons 230 to 463 and 600 to 790. Sequencing was
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intended for all 30 AL samples including the recrudes-
cent strain, amplification failed due to long storage con-
ditions of the DNA and general problems with these
particular PCRs for the day 0 counterpart of the one
possible recrudescent sample on day 70 and for many
PCRs with the ATP1 and ATP2 primers. All gained
sequences could be identified as part of the pfserca gene
with the reference strain Dd2. 12 mutations or SNPs
were identified, six new and six described. The pre-
viously reported E431K mutant codon was the most fre-
quent occurring in seven isolates [29,30]. Each of the
other genotypes was detected only once. No sample
showed more than two mutations. Three of the new
mutations were non synonymous and the other three
synonymous (Tables 3 and 4). The sample from day 70
yielded no mutation in the pfserca gene.
No mutations were detected in the amplified regions
of the pfcytb gene of 2 recrudescent strains in the AP
group.
Discussion
High cure rates of AL have also been reported from
other recent studies with 28 days of follow-up in Ethio-
pia [31,32]. For the detection of late recrudescences,
follow-up periods longer than 28 days seem more
appropriate. In this study, genotyping indicated a recru-
descence on day 70 in one patient treated with AL. The
msp-1 gene and especially the RFLP results with
different enzymes (Hinf III, Dde I, Rsa I) of the msp-2
gene showed the same molecular pattern for the two
samples from day 0 and day 70 [25]. Additionally, a
short sequence of the msp-1 gene was amplified, as the
amplification of the pfserca sequence failed. The two
sequences fully matched, blasting showed a difference
between the Ethiopian sequence and other published
strains from different regions of 90-96% [33]. Though,
re-infection with a very similar clone not to be differen-
tiated by molecular methods is still possible regarding
the moderate transmission area. This particular molecu-
lar RFLP pattern was found in almost a quarter of all
samples. Overall, at least six different patterns in differ-
ent combinations, four being predominant, were
observed. (Data not shown) The two particular samples
from day 0 and day 70 showed the tyrosine mutation at
codon 86 of the pfmdr1 gene.
Table 1 Clinical and parasitological treatment failures
PCR-corrected failure rates* AL Q AP
Number of patients with recrudescence/total number of patients
(day)
1/30 (70)** 4/35 (24, 28, 28,
40)
2/32(28, 28)
Drug resistance associated polymorphisms 1. pfserca gene
2. pfmdr codon 86N
1. pfmdr codon
86N
1. cytb gene codon 268
2. dhfr triple mutation (51I+59R
+108N)
3. dhfr codon A16V
Polymorphisms in recrudescent samples n (%) 1. 0 (0)
2. 0 (0)
1. 0 (0) 1. 0 (0)
2. 2 (100)
3. 1 (50)
*P. falciparum: Genotyping by PCR and RFLP patterns of the msp-1 and msp-2 gene
**Possible Recrudescence
Table 2 Prevalence of pfdhfr and pfmdr1 mutations
Genetic
Polymorphism
Overall prevalence rate mutation/total n
(%)
DHFR A16V 1/97 (1.1)
DHFR N51I 83/84* (98.8)
DHFR C59R 85/97 (87.6)
DHFR S108N 97/97 (100.0)
DHFR S108T 0/97 (0.0)
DHFR (51I,59R,108N) 70/84 (83.3)
DHFR I164L 0/97 (0.0)
pfmdr N86Y 82/97 (84.5)
*RFLP outcome not distinguishable for 13 samples
Table 3 Prevalence of wild type and mutant codons in
the pfserca gene
Codon Wild type
n (%)
Mutation
n (%)
E237A 6/7 (85.7) 1/7 (14.3)
H243Y 7/7 (100.0) 0/7 (0.0)
L263E 7/7 (100.0) 0/7 (0.0)
L263L 6/7 (85.7) 1/7 (14.3)
L402V 14/15 (93.3) 1/15 (6.7)
E431K 5/12 (41.7) 7/12 (58.3)
N460N 12/12 (100.0) 0/12 (0.0)
A623E 23/24 (95.8) 1/24 (4.2)
A630S 23/23 (100.0) 0/23 (0.0)
R682R 22/23 (95.7) 1/23 (4.4)
N683E 22/23 (95.7) 1/23 (4.4)
N683K 22/23 (95.7) 1/23 (4.4)
K766K 26/27 (96.3) 1/27 (3.7)
K767E 26/27 (96.3) 1/27 (3.7)
K767R 26/27 (96.3) 1/27 (3.7)
S769N 26/27 (96.3) 127 (3.7)
K771E 25/25 (100.0) 0/25 (0.0)
K776N 24/24 (100.0) 0/24 (0.0)
Fragments spanning codons 230 to 463 and 600 to 790, respectively, ref. [29])
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The previously described mutant codon S769N being
associated with in vitro resistance in French Guiana was
found in a clinical sensitive sample [15,17]. Other
recently published mutations were not detected in the
amplified regions of the study samples but the pfserca
gene was only partly sequenced for 31 samples [34].
Overall, 12 different mutations were observed in an AL-
naive population, some of these mutations seem to be
globally distributed as reports from Asia and South
Africa indicate and not to be associated with drug resis-
tance or caused by drug pressure [34]. The next step
will be the comparison of the polymorphisms in these
isolates with about 350 P. falciparum samples, recently
collected in Jimma area. Almost four years after the
broad introduction of AL in Ethiopia, selection or disap-
pearence of certain mutations may have occured.
A study conducted in southern Ethiopia prior to the
introduction of ACTs showed a prevalence of pfmdr1
86Y of 81% and of the mutant pfcrt 76 of 100% [35].
High prevalence rates of the pfmdr1 mutation 86Y were
therefore expected. Q has been used for decades in
Ethiopia as second line treatment and treatment for
severe malaria, treatment failures occured sporadically.
Exact data were not published. Due to intensive use in
Thailand for example, failure rates with Quinine raised
dramatically. Attempts to show a clear correlation of
drug resistance with molecular patterns has failed so far,
mutations in the pfmdr1 gene were discussed [36]. All
treatment failures in the Q group showed the SNP of
pfmdr 86Y associated with chloroquine resistance but
increased sensitivity to quinine in in vitro studies. No
selection to 86N in the recrudescent samples was
observed but the small sample size and few treatment
failures allow no conclusions [37].
The high prevalence of dhfr mutations is likely caused
by wide use of proguanil, active metabolite of sulpha-
doxine/pyrimethamine, prior to AL introduction in the
area. In the above cited study from Ethiopia, the pfdhfr
mutations N108, I51 and R59 were present in 100%,
97% and 90%, respectively, of all investigated samples,
the pfdhfr triple mutations (51I+59R+108N) occurred in
87% of the isolates [35]. Another study from Jimma
reported 100% prevalence of the 108N and 51I muta-
tions, and 54% prevalence of the pfdhfr triple mutation
[38]. The occurrence of the triple mutations in both
recrudescent isolates of the AP group was therefore very
likely. Nevertheless, the idea of these mutations being a
necessary but not sufficient cause of resistance to pro-
guanil is supported. The circumstance that the only
mutation at codon A16V occurred in the recrudescent
sample may have contributed at least to the late treat-
ment failure at day 28.
Although the combination AP has never been broadly
used in the study region before, it simply served as
negative control in the ototoxicity trial, two parasitologi-
cal failures occurred, one was clinical symptomatic.
Treatment failures have been reported from Africa.
Some have been associated with mutations in the cytb
gene, since in vitro resistance to AP was correlated espe-
cially with mutations at codon 268 of that gene [39-41].
A molecular survey from Ethiopia and Gabon detected
no mutations in the pfcytb gene of samples from Ethio-
pia but several different mutations in 10% of Gabonian
samples, although AP was not in use in both regions
[42]. Spontaneous mutations are rare but seem to
occure independent from drug pressure. Both recrudes-
cent isolates in this study showed no mutations in the
amplified sequence containing codon 268 but not the
whole gene was sequenced and other mutations are pos-
sible. Treatment failures may also be due to limited
bioavailability in some patients. However, as AP is
highly recommended as prophylaxis for travellers to
Ethiopia, a failure rate of 6.3% was quite alarming.
Conclusion
As expected, there were no signs of clinical or parasito-
logical failures in the AL group except for one possible
very late recrudescence on day 70 at the time of ACT
introduction. The patterns of mutations in general fit
with the situation of long-lasting chloroquine and SP
usage before the presence of ACT in this area. Q is the
national second-line treatment and backup, however its
use will be compromised by the degree of resistance
Table 4 List of pfserca non synonymous and synonymous
mutations found
Nucleotide mutation amino acid
(NS; Syn)
No. of mutations Reference
A709C E237A 1 New
C726T H243Y 0 29
T787G, T788A L263E 0 29
A789G L263L 1 New
1204G L402V 1 29
G1291A E431K 7 29
T1380C N460N 0 30
C1867A A623E 1 29
G1887T A630S 0 29
A2045G R682R 1 New
A2046G, T2048A N683E 1 29
T2048A N683K 1 30
A2297G K766K 1 New
A2298G K767E 1 New
A2299G K767R 1 New
G2305A S769N 1 29
A2310G K771E 0 29
G2327T K776N 0 29
Fragments spanning codons 230 to 463 and 600 to 790, respectively, ref. [29])
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shown in our results. AL seems to be the best treatment
option and must be available consistently. Moreover
continuous surveillance should be established in the
area for AL as data from South East Asia showed
decreased susceptibility of P. falciparum for ACT several
years after introduction. A similar development could
possibly be expected in Ethiopia.
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